10-Q

United States

Securities and Exchange Commission

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission File No: 0-11740

MESA LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Colorado	84-0872291
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification number)
12100 West Sixth Avenue
Lakewood, Colorado	80228
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (303) 987-8000

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name on each exchange on which registered
Common Stock, no par value	MLAB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934, during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒   No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐     No ☒

Indicate the number of shares outstanding of each of the Issuer’s classes of common stock, as of the latest practicable date:

There were 5,336,807 shares of the Issuer’s common stock, no par value, outstanding as of October 27, 2022.

Table of Contents

Part I. Financial Information		1
	Item 1. Financial Statements	1
	Condensed Consolidated Balance Sheets	1
	Condensed Consolidated Statements of Operations	2
	Condensed Consolidated Statements of Comprehensive (Loss) Income	3
	Condensed Consolidated Statements of Cash Flows	4
	Condensed Consolidated Statements of Stockholders’ Equity	5
	Notes to Condensed Consolidated Financial Statements	6
	Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
	Item 3.  Quantitative and Qualitative Disclosures about Market Risk	20
	Item 4.  Controls and Procedures	21
Part II. Other Information		22
	Item 1.  Legal Proceedings	22
	Item 1A.  Risk factors	22
	Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds	22
	Item 6.  Exhibits	23
	Signatures	24
	Exhibit 31.1 Certifications Pursuant to Rule 13a-14(a)
	Exhibit 31.2 Certifications Pursuant to Rule 13a-14(a)
	Exhibit 32.1 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350
	Exhibit 32.2 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350

Part I. Financial Information

Item 1. Financial Statements

Mesa Laboratories, Inc.

Condensed Consolidated Balance Sheets

(unaudited)

(dollars in thousands, except share amounts)

	September 30,			March 31,
	2022			2022
ASSETS
Current assets:
Cash and cash equivalents	$	32,377		$	49,346
Accounts receivable, less allowance for doubtful accounts of $1,013 and $630, respectively		41,809			41,224
Inventories		28,039			24,606
Prepaid expenses and other		14,035			9,142
Total current assets		116,260			124,318
Property, plant and equipment, net of accumulated depreciation of $18,826 and $17,726, respectively		28,222			28,620
Deferred tax asset		647			1,318
Other assets		10,825			11,830
Intangibles, net		222,271			250,117
Goodwill		278,006			291,166
Total assets	$	656,231		$	707,369
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	7,738		$	7,897
Accrued payroll and benefits		7,481			14,717
Unearned revenues		13,831			13,830
Other accrued expenses		12,456			11,611
Total current liabilities		41,506			48,055
Deferred tax liability		36,847			39,224
Other long-term liabilities		6,826			7,924
Credit Facility		27,000			49,000
Convertible senior notes, net of discounts and debt issuance costs		169,816			169,365
Total liabilities		281,995			313,568
Stockholders’ equity:
Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,336,271 and 5,265,627 shares, respectively		324,905			313,460
Retained earnings		74,848			76,675
Accumulated other comprehensive (loss) income		(25,517	)		3,666
Total stockholders’ equity		374,236			393,801
Total liabilities and stockholders’ equity	$	656,231		$	707,369

See accompanying notes to Condensed Consolidated Financial Statements.

Page 1

Mesa Laboratories, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

(in thousands, except per share data)

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Revenues	$	58,749		$	35,840		$	109,202		$	70,760
Cost of revenues		22,363			12,700			41,475			25,409
Gross profit		36,386			23,140			67,727			45,351
Operating expenses:
Selling		9,200			4,643			19,223			9,501
General and administrative		18,202			11,683			38,414			23,102
Research and development		4,989			2,613			10,689			5,424
Total operating expenses		32,391			18,939			68,326			38,027
Operating income (loss)		3,995			4,201			(599	)		7,324
Nonoperating expense (income):
Interest expense and amortization of debt discount		1,214			815			2,228			1,629
Other (income), net		(603	)		(1,157	)		(799	)		(266	)
Total nonoperating expense (income)		611			(342	)		1,429			1,363
Earnings (loss) before income taxes		3,384			4,543			(2,028	)		5,961
Income tax provision (benefit)		2,078			823			(1,896	)		246
Net income (loss)	$	1,306		$	3,720		$	(132	)	$	5,715
Earnings (loss) per share:
Basic	$	0.25		$	0.71		$	(0.02	)	$	1.10
Diluted	$	0.24		$	0.70		$	(0.02	)	$	1.07
Weighted-average common shares outstanding:
Basic		5,323			5,211			5,298			5,182
Diluted		5,364			5,344			5,298			5,324

See accompanying notes to Condensed Consolidated Financial Statements.

Page 2

Mesa Laboratories, Inc.

Condensed Consolidated Statements of Comprehensive (Loss) Income

(unaudited)

(in thousands) 

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Net income (loss)	$	1,306		$	3,720		$	(132	)	$	5,715
Other comprehensive (loss) income:
Foreign currency translation adjustments		(13,226	)		(6,503	)		(29,183	)		(1,132	)
Comprehensive (loss) income	$	(11,920	)	$	(2,783	)	$	(29,315	)	$	4,583

See accompanying notes to Condensed Consolidated Financial Statements.

Page 3

Mesa Laboratories, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

	Six Months Ended September 30,
	2022			2021
Cash flows from operating activities:
Net (loss) income	$	(132	)	$	5,715
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization		16,189			8,849
Stock-based compensation expense		7,803			4,236
Non-cash interest and debt amortization		452			443
Deferred taxes		(908	)		-
Other		(636	)		(224	)
Cash (used in) provided by changes in operating assets and liabilities:
Accounts receivable, net		(2,657	)		1,065
Inventories		(4,065	)		(808	)
Prepaid expenses and other assets		(3,052	)		(1,473	)
Accounts payable		243			(167	)
Accrued liabilities and taxes payable		(5,869	)		(4,596	)
Unearned revenues		378			983
Net cash provided by operating activities		7,746			14,023
Cash flows from investing activities:
Purchases of property, plant and equipment		(1,864	)		(1,591	)
Net cash (used in) investing activities		(1,864	)		(1,591	)
Cash flows from financing activities:
Payments of debt		(22,000	)		-
Dividends		(1,695	)		(1,658	)
Proceeds from the exercise of stock options		3,642			3,081
Net cash (used in) provided by financing activities		(20,053	)		1,423
Effect of exchange rate changes on cash and cash equivalents		(2,798	)		574
Net (decrease) increase in cash and cash equivalents		(16,969	)		14,429
Cash and cash equivalents at beginning of period		49,346			263,865
Cash and cash equivalents at end of period	$	32,377		$	278,294

See accompanying notes to Condensed Consolidated Financial Statements.

Page 4

Mesa Laboratories, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(unaudited)

(dollars in thousands, except per share data)

	Common Stock
	Number of Shares		Amount		Retained Earnings			AOCI*			Total
March 31, 2022		5,265,627	$	313,460	$	76,675		$	3,666		$	393,801
Exercise of stock options and vesting of restricted stock units		31,681		1,436		-			-			1,436
Dividends paid, $0.16 per share		-		-		(843	)		-			(843	)
Stock-based compensation expense		-		3,432		-			-			3,432
Foreign currency translation		-		-		-			(15,957	)		(15,957	)
Net (loss)		-		-		(1,438	)		-			(1,438	)
June 30, 2022		5,297,308	$	318,328	$	74,394		$	(12,291	)	$	380,431
Exercise of stock options and vesting of restricted stock units		38,963		2,206		-			-			2,206
Dividends paid, $0.16 per share		-		-		(852	)		-			(852	)
Stock-based compensation expense		-		4,371		-			-			4,371
Foreign currency translation		-		-		-			(13,226	)		(13,226	)
Net income		-		-		1,306			-			1,306
September 30, 2022		5,336,271	$	324,905	$	74,848		$	(25,517	)	$	374,236

	Common Stock
	Number of Shares		Amount			Retained Earnings			AOCI*			Total
March 31, 2021		5,140,568	$	317,652		$	72,459		$	16,116		$	406,227
Exercise of stock options and vesting of restricted stock units		58,324		1,089			-			-			1,089
Dividends paid, $0.16 per share		-		-			(824	)		-			(824	)
Stock-based compensation expense		-		2,197			-			-			2,197
Foreign currency translation		-		-			-			5,371			5,371
Cumulative adjustment due to adoption of ASU No. 2020-06		-		(22,735	)		5,683			-			(17,052	)
Net income		-		-			1,995			-			1,995
June 30, 2021		5,198,892	$	298,203		$	79,313		$	21,487		$	399,003
Exercise of stock options and vesting of restricted stock units		24,340		1,992			-			-			1,992
Dividends paid, $0.16 per share		-		-			(834	)		-			(834	)
Stock-based compensation expense		-		2,039			-			-			2,039
Foreign currency translation		-		-			-			(6,503	)		(6,503	)
Net income		-		-			3,720			-			3,720
September 30, 2021		5,223,232	$	302,234		$	82,199		$	14,984		$	399,417

*Accumulated Other Comprehensive (Loss) Income.

See accompanying notes to Condensed Consolidated Financial Statements.

Page 5

Mesa Laboratories, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

(dollar and share amounts in thousands, unless otherwise specified)

Note 1. Description of Business and Summary of Significant Accounting Policies

Description of Business

In this quarterly report on Form 10-Q, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries is collectively referred to as “we,” “us,” “our,” the “Company” or “Mesa.”

We are a multinational manufacturer, developer, and seller of life science tools and critical quality control products and services, many of which are sold into niche markets that are driven by regulatory requirements. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe, and Asia Pacific, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins.

As of September 30, 2022, we managed our operations in four reportable segments, or divisions:

● Clinical Genomics - develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics and oncology related applications.

● Sterilization and Disinfection Control - manufactures and sells biological, cleaning, and chemical indicators which are used to assess the effectiveness of sterilization and disinfection processes in the hospital, medical device, and pharmaceutical industries. The division also provides testing and laboratory services, mainly to the dental industry. 

● Biopharmaceutical Development - develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufacture of biotherapeutic drugs. 

● Calibration Solutions - develops, manufactures, and sells quality control and calibration products used to measure or calibrate temperature, pressure, pH, humidity, and other chemical or physical parameters for health and safety purposes, primarily in hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. 

Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for the fair statement of our financial position and results of operations. The results of operations for the interim periods are not necessarily indicative of results that may be achieved for the entire year. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. We made no material changes to the application of our significant accounting policies that were disclosed in our Form 10-K. This quarterly report should be read in conjunction with the consolidated financial statements included in our annual report on Form 10-K for the year ended  March 31, 2022.

Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year, references to the first quarter of fiscal year 2023 refer to the period from April 1, 2022 through June 30, 2022, and references to the second quarter of fiscal year 2023 refer to the period from July 1, 2022 through September 30, 2022. References to “fiscal year 2022” refer to the fiscal year ended March 31, 2022, and to “fiscal year 2023” refer to the fiscal year ending March 31, 2023.

Prior Period Reclassification

Certain amounts presented for prior periods related to the Biopharmaceutical Development division in Note 3. "Revenue Recognition" have been reclassified out of revenues from consumables and into revenues from hardware and services. These reclassifications have not resulted in any change to the Condensed Consolidated Financial Statements for and periods presented in this Form 10-Q.

Risks and Uncertainties

The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgement about the outcome of future events. The business and economic uncertainty resulting from the novel coronavirus pandemic ("COVID-19"), supply chain challenges, cost pressure and the overall effects of the current high inflation environment on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates.

Page 6

 

Recently Issued Accounting Pronouncements

We have reviewed all recently issued accounting pronouncements and have concluded that they are either not applicable to us or are not expected to have a significant impact on our consolidated financial statements.

Note 2. Significant Transactions

On October 20, 2021, we completed the acquisition of Agena Bioscience, Inc. (“Agena”) for $300,793, net of cash acquired but inclusive of working capital adjustments (the “Agena Acquisition”). The Agena Acquisition aligned with our overall acquisition strategy, moved our business towards the life sciences tools sector, and expanded our market opportunities, particularly in Asia. Agena is a leading clinical genomics tools company that develops, manufactures, markets, and supports proprietary instruments and related consumables and services that enable genetic analysis for a broad range of diagnostic and research applications. Using Agena's MassARRAY® instruments and chemical reagent solutions, customers can analyze DNA samples for a variety of high volume clinical testing applications, such as inherited genetic disease testing, pharmacogenetics, various oncology tests, infectious disease testing, and other highly differentiated applications.

We funded the acquisition and transactions relating thereto with cash on hand and borrowings under the Credit Facility (as defined below). Of the cash consideration we paid, approximately $267,000 represented cash consideration to holders of Agena’s preferred and common stock, approximately $2,000 represented cash consideration paid for the settlement of Agena’s warrants, and approximately $31,800 represented cash consideration for the settlement of Agena's vested stock options as of the closing date.

Agena Preliminary Purchase Price Allocation

During the three months ended September 30, 2022, we continued analyses of the valuation of net assets acquired in the Agena Acquisition. This preliminary purchase price allocation is subject to revision as more detailed analyses are completed with respect to prepaid taxes, tax accruals, and deferred tax positions.

The following table summarizes the allocation of the purchase price as of October 20, 2021:

	Life (in years)		Amount
Cash and cash equivalents			$	7,544
Accounts receivable				11,100
Other current assets				25,480
Total current assets				44,124
Property, plant and equipment/noncurrent assets				15,832
Deferred tax asset				811
Intangible assets:
Goodwill		N/A		136,260
Customer relationships		12		103,800
Intellectual property		8		45,400
Tradenames		12		15,700
Total Assets acquired			$	361,927
Accounts payable				2,174
Unearned revenues				2,713
Other current liabilities				12,217
Total current liabilities				17,104
Deferred tax liability				28,223
Other noncurrent liabilities				8,263
Total liabilities assumed			$	53,590
Total purchase price, net of cash acquired			$	300,793

Acquired Goodwill

Acquired goodwill of $136,260, all of which is allocated to the Clinical Genomics reportable segment, represents the value expected to arise from expanded market opportunities, expected synergies, and assembled workforce, none of which qualify as amortizable intangible assets. The goodwill acquired is not deductible for income tax purposes.

Page 7

 

Unaudited Pro Forma Information

The following unaudited pro forma financial information presents the combined results of operations of Mesa and Agena as if the acquisition had occurred on April 1, 2021 after giving effect to certain pro forma adjustments. 

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Pro forma total revenues	$	58,749	$	53,521	$	109,202	$	107,074
Pro forma net income		1,504		1,916		329		4,437

The pro forma financial information includes adjustments that are directly attributable to the business combinations and are factually supportable. The pro forma adjustments include incremental amortization of intangible assets, additional stock-based compensation expense for key Agena employees, the removal of interest expense attributable to Agena’s external debt that was paid off as part of the acquisition, and the pro forma tax impact for such adjustments. Cost savings or operating synergies expected to result from the acquisition are not included in the pro forma results. For the three and six months ended September 30, 2022, the pro forma financial information excludes $267 and $623 of non-recurring acquisition-related expenses, respectively. These pro forma results are illustrative only and not indicative of the actual results of operations that would have been achieved nor are they indicative of future results of operations.

Note 3. Revenue Recognition

We develop, manufacture, market, sell and maintain life sciences tools and quality control instruments and related software, consumables, and services.

Sales of hardware, such as instruments used for molecular and genetic analysis, protein synthesizers, medical meters, wireless sensor systems, and data loggers are generally driven by our acquisition of new customers, growth of existing customers, or customers replacing existing equipment. Hardware sales  may be offered with accompanying perpetual or annual software licenses, which in some cases are required for the hardware to function. We also offer discrete and ongoing service and maintenance contracts on our instruments.

Consumables are typically used on a one-time basis and require frequent replacement in our customers' operating cycles. Consumables such as reagents used for molecular and genetic analysis or solutions used for protein synthesis are critical to the ongoing use of our instruments. Consumables such as biological indicator test strips are used on a standalone basis.

We evaluate our revenues internally based on operating segment, the timing of revenue generation, and the nature of goods and services provided. Typically, discrete revenue is recognized upon shipment of a product or upon completion of a service, while contracted revenue is recognized over a period of time reflective of the performance obligation period in the applicable contract. The significant majority of our revenues and related receivables are generated from contracts with customers that are 12 months or less in duration.

The following tables present disaggregated revenues for the three and six months ended September 30, 2022 and 2021, respectively:

	Three Months Ended September 30, 2022
	Clinical Genomics		Sterilization and Disinfection Control		Biopharmaceutical Development		Calibration Solutions		Total
Discrete Revenues
Consumables	$	11,366	$	14,704	$	4,000	$	865	$	30,935
Hardware and Software		5,527		218		5,988		5,980		17,713
Services		374		543		995		3,587		5,499
Contracted Revenues
Services and Software		1,168		1,499		1,161		774		4,602
Total Revenues	$	18,435	$	16,964	$	12,144	$	11,206	$	58,749

	Three Months Ended September 30, 2021
	Clinical Genomics*		Sterilization and Disinfection Control		Biopharmaceutical Development		Calibration Solutions		Total
Discrete Revenues
Consumables	$	-	$	11,985	$	3,717	$	860	$	16,562
Hardware and Software		-		85		4,942		6,548		11,575
Services		-		493		864		2,981		4,338
Contracted Revenues
Services and Software		-		1,470		1,032		863		3,365
Total Revenues	$	-	$	14,033	$	10,555	$	11,252	$	35,840

	Six Months Ended September 30, 2022
	Clinical Genomics		Sterilization and Disinfection Control		Biopharmaceutical Development		Calibration Solutions		Total
Discrete Revenues
Consumables	$	22,276	$	26,932	$	7,664	$	1,719	$	58,591
Hardware and Software		7,632		524		10,812		11,673		30,641
Services		902		1,308		2,180		6,248		10,638
Contracted Revenues
Services and Software		2,130		2,974		2,455		1,773		9,332
Total Revenues	$	32,940	$	31,738	$	23,111	$	21,413	$	109,202

	Six Months Ended September 30, 2021
	Clinical Genomics*		Sterilization and Disinfection Control		Biopharmaceutical Development		Calibration Solutions		Total
Discrete Revenues
Consumables	$	-	$	24,861	$	7,489	$	1,812	$	34,162
Hardware and Software		-		245		8,335		13,630		22,210
Services		-		1,194		1,446		5,216		7,856
Contracted Revenues
Services and Software		-		2,883		2,162		1,487		6,532
Total Revenues	$	-	$	29,183	$	19,432	$	22,145	$	70,760

*Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021. 

Page 8

 

Revenues from external customers are attributed to individual countries based upon the locations to which the products are shipped or exported, or the locations where services are performed, as follows:

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
United States	$	30,989	$	19,384	$	60,111	$	37,839
China		7,480		1,552		11,177		3,717
Other		20,280		14,904		37,914		29,204
Total revenues	$	58,749	$	35,840	$	109,202	$	70,760

Other than China, no foreign country exceeds 10% of total revenues.

Contract Balances

Our contracts have varying payment terms and conditions. Some customers prepay for products and services, resulting in unearned revenues or customer deposits, called contract liabilities. Short-term contract liabilities are included within other accrued expenses and unearned revenues in the accompanying Condensed Consolidated Balance Sheets, and long-term contract liabilities are included within other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets.

A summary of contract liabilities is as follows:

Contract liabilities as of March 31, 2022	$	15,069
Prior year liabilities recognized in revenues during the six months ended September 30, 2022		(3,087	)
Contract liabilities added during the six months ended September 30, 2022, net of revenues recognized		4,284
Contract liabilities balance as of September 30, 2022	$	16,266

Contract liabilities primarily relate to service contracts with original expected service durations of 12 months or less and will be recognized to revenue as time passes.

Note 4. Fair Value Measurements

Our financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, obligations under trade accounts payable, and debt. Due to their short-term nature, the carrying values for cash and cash equivalents, trade accounts receivable, and trade accounts payable approximate fair value. We measure our cash equivalents at fair value using quoted market prices in an active market, and we classify them within Level 1 of the fair value hierarchy. 

Historically, the financial instruments that subject us to the highest concentration of credit risk are cash and cash equivalents and accounts receivable. It is our policy to invest in highly liquid cash equivalent financial instruments with high credit ratings and to maintain low single issuer exposure (except U.S. treasuries). Concentration of credit risk with respect to accounts receivable is limited to customers to which we make significant sales. We reserve an allowance for potential write-offs of accounts receivable using historical collection experience and current and expected future economic and market conditions, but we have not written off any significant accounts to date. To manage credit risk, we consider the creditworthiness of new and existing customers, and we regularly review outstanding balances and payment histories. We  may require pre-payments from customers under certain circumstances and  may limit future purchases until payments are made on past due amounts.

We have outstanding $172,500 aggregate principal of 1.375% convertible senior notes due  August 15, 2025 (the "Notes"). We estimate the fair value of the Notes based on the last actively traded price or observable market input preceding the end of the reporting period and the fair value is approximately correlated to our stock price. The estimated fair value and carrying value of the Notes were as follows:

	September 30, 2022				March 31, 2022
	Carrying Value		Fair Value (Level 2)		Carrying Value		Fair Value (Level 2)
Notes	$	169,816	$	143,930	$	169,365	$	185,438

Assets recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a nonrecurring basis include items such as property and equipment, operating lease assets, goodwill, and other intangible assets. These assets are measured at fair value if determined to be impaired. Fair values assigned to assets acquired and liabilities assumed in the Agena Acquisition, except deferred revenues, were measured using Level 3 inputs. There were no transfers between the levels of the fair value hierarchy during the three and six months ended September 30, 2022 or 2021, respectively.

Page 9

 

Note 5. Supplemental Balance Sheets Information

Inventories consist of the following:

	September 30, 2022		March 31, 2022
Raw materials	$	16,433	$	14,172
Work in process		1,833		4,419
Finished goods		9,773		6,015
Total inventories	$	28,039	$	24,606

Prepaid expenses and other consist of the following:

	September 30, 2022		March 31, 2022
Prepaid expenses	$	3,364	$	2,871
Deposits		2,787		1,410
Prepaid income taxes		4,343		2,536
Other current assets		3,541		2,325
Total prepaid expenses and other	$	14,035	$	9,142

Accrued payroll and benefits consist of the following:

	September 30, 2022		March 31, 2022
Bonus payable	$	3,348	$	7,468
Wages and paid-time-off payable		2,081		3,677
Payroll related taxes		1,349		2,069
Other benefits payable		703		1,503
Total accrued payroll and benefits	$	7,481	$	14,717

Note 6. Goodwill and Intangible Assets, Net

Finite-lived intangible assets consist of the following:

	September 30, 2022							March 31, 2022
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Customer relationships	$	228,914	$	(73,566	)	$	155,348	$	244,157	$	(67,469	)	$	176,688
Intellectual property		64,230		(15,762	)		48,468		65,893		(12,620	)		53,273
Other intangibles		24,323		(5,868	)		18,455		25,350		(5,194	)		20,156
Total	$	317,467	$	(95,196	)	$	222,271	$	335,400	$	(85,283	)	$	250,117

Amortization expense for finite-lived intangible assets acquired in a business combination was as follows:

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Amortization in cost of revenues	$	1,691	$	322	$	3,399	$	650
Amortization in general and administrative expense		5,415		3,435		11,027		6,923
Total	$	7,106	$	3,757	$	14,426	$	7,573

For the following fiscal years ending March 31, amortization expense is estimated as follows:

Remainder of 2023	14,030
2024	27,550
2025	25,986
2026	25,247
2027	24,764

The change in the carrying amount of goodwill was as follows:

	Clinical Genomics			Sterilization and Disinfection Control			Biopharmaceutical Development			Calibration Solutions			Total
March 31, 2022	$	135,914		$	29,750		$	88,265		$	37,237		$	291,166
Effect of foreign currency translation		(395	)		(894	)		(12,145	)		(106	)		(13,540	)
Goodwill related to Agena acquisition		380			-			-			-			380
September 30, 2022	$	135,899		$	28,856		$	76,120		$	37,131		$	278,006

Note 7. Indebtedness

Credit Facility

We maintain a senior credit facility (the “Credit Facility”) that includes 1) a revolving credit facility in an aggregate principal amount of up to $75,000, 2) a swingline loan in an aggregate principal amount not exceeding $5,000, and 3) letters of credit in an aggregate stated amount not exceeding $2,500.  The Credit Facility matures in March 2025. The Credit Facility also provides for an incremental term loan or an increase in revolving commitments in an aggregate principal amount of at a minimum $25,000 and at a maximum $75,000, subject to the satisfaction of certain conditions and lender considerations. As of September 30, 2022, we had $27,000 outstanding under the Credit Facility. 

Amounts borrowed under the Credit Facility bear interest at either a base rate or a Eurodollar rate, plus an applicable spread. The weighted average interest rate on borrowing under our line of credit was 4.9% and 1.5% as of September 30, 2022 and March 31, 2022, respectively. We are obligated to pay quarterly unused commitment fees of between 0.15% and 0.35% of the Credit Facility’s aggregate principal amount, based on our leverage ratio. 

Page 10

 

The financial covenants in the Credit Facility include a maximum leverage ratio of 5.0 to 1.0 for the period ended September 30, 2022, except that we  may have a leverage ratio of 5.75 to 1.0 for a period of four consecutive quarters following a permitted acquisition. The Credit Facility also stipulates a minimum fixed charge coverage ratio of 1.25 to 1.0. Other covenants include restrictions on our ability to incur debt, grant liens, make fundamental changes, engage in certain transactions with affiliates, or conduct asset sales. As of  September 30, 2022, we were in compliance with all covenants.

In October 2022, we repaid $2,000 of the outstanding balance on our Credit Facility.

Convertible Notes 

On August 12, 2019, we issued an aggregate principal amount of $172,500 of Notes. The net proceeds from the Notes, after deducting underwriting discounts and commissions and other related offering expenses payable by us, were approximately $167,056. The Notes mature on August 15, 2025, unless earlier repurchased or converted, and bear interest at a rate of 1.375% payable semi-annually in arrears on February 15 and August 15 each year beginning on February 15, 2020. 

Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock, or a combination of cash and shares of our common stock, at our election. Our current intent is to settle conversions entirely in shares of common stock. We will reevaluate this policy from time to time as we receive conversion notices from note holders. The circumstances necessary for conversion were not met during the three months ended September 30, 2022. As of September 30, 2022, the Notes are classified as a long-term liability on our Condensed Consolidated Balance Sheets as the circumstances necessary for conversion were not satisfied as of the end of the period. The if-converted value of the Notes did not exceed the principal balance as of  September 30, 2022.

The net carrying amount of the Notes was as follows:

	September 30, 2022			March 31, 2022
Principal outstanding	$	172,500		$	172,500
Unamortized debt issuance costs		(2,684	)		(3,135	)
Net carrying value	$	169,816		$	169,365

We recognized interest expense on the Notes as follows:

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Coupon interest expense at 1.375%	$	593	$	593	$	1,186	$	1,186
Amortization of debt discounts and issuance costs		227		222		452		443
Total interest and amortization of debt issuance costs	$	820	$	815	$	1,638	$	1,629

The effective interest rate on the notes is approximately 1.9%.

Note 8. Stockholders' Equity

Stock-Based Compensation

During the six months ended September 30, 2022, we issued stock options, restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs") pursuant to the Mesa Laboratories, Inc. 2021 Equity Incentive Plan (the "2021 Equity Plan"), which authorizes the issuance of 330 shares of common stock to eligible participants.

Expense recognized related to stock-based compensation is as follows: 

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Stock-based compensation expense	$	4,371		$	2,039		$	7,803		$	4,236
Amount of income tax (benefit) recognized in earnings		(89	)		(719	)		(2,081	)		(3,504	)
Stock-based compensation expense, net of tax	$	4,282		$	1,320		$	5,722		$	732

Stock-based compensation expense is included in cost of revenues, selling, general and administrative, and research and development expense in the accompanying unaudited Condensed Consolidated Statements of Operations.

Page 11

 

The following is a summary of stock option award activity for the six months ended September 30, 2022:

	Stock Options
	Shares Subject to Options			Weighted- Average Exercise Price per Share		Weighted-Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding as of March 31, 2022		202		$	167.14		2.9	$	18,261
Awards granted		42			185.57
Awards forfeited or expired		(6	)		227.42
Awards exercised		(42	)		101.34
Outstanding as of September 30, 2022		196		$	183.13		3.2	$	1,978

The stock options granted during the six months ended September 30, 2022 vest in equal installments on the first, second, and third anniversary of the grant date.

The following is a summary of RSU award activity for the six months ended September 30, 2022:

	Time-Based Restricted Stock Units					Performance-Based Restricted Stock Units
	Number of Shares			Weighted- Average Grant Date Fair Value per Share		Number of Shares			Weighted- Average Grant Date Fair Value per Share
Outstanding as of March 31, 2022(1)		51		$	252.86		55		$	288.45
Awards granted(1)		39			187.44		19			172.15
Performance adjustment(2)		-			-		2			202.00
Awards forfeited		(5	)		241.94		-			-
Awards distributed(2)		(24	)		247.29		(10	)		202.00
Outstanding as of September 30, 2022(1)		61		$	214.47		66		$	265.39

⁽¹⁾ Balances for performance-based restricted stock units ("PSUs") are reflected at target.

⁽²⁾ During the six months ended September 30, 2022, the fiscal year 2020 PSUs vested and were distributed at 126% of target, based on actual performance results and completion of service conditions. 

The outstanding time-based RSUs vest and settle in shares of our common stock on a one-for-one basis. Substantially all of the RSUs granted during the six months ended September 30, 2022 vest in equal installments on the first, second, and third anniversary of the grant date. We recognize the expense relating to RSUs, net of estimated forfeitures, on a straight-line basis over the vesting period.

PSUs vest upon completion of the service period described in the award agreement and based on achievement of the performance targets described in the award agreements. We recognize the expense relating to the performance-based RSUs based on the probable outcome of achievement of the performance targets on a straight-line basis over the service period. 

During the six months ended September 30, 2022, the Compensation Committee of the Board of Directors created a plan to award 19 PSUs at target (the "FY 23 PSUs") that are subject to both service and performance conditions to eligible employees. The performance period for the FY 23 PSUs is from April 1, 2022 until March 31, 2023 and the service period is from April 1, 2022 until March 31, 2025. Of the total FY 23 PSUs granted, 13 vest based on our achievement of specific performance criteria during fiscal year 2023 and they have a grant date fair value of $185.57. The remaining 6 awards will be settled in shares of our common stock, but they are subject to performance criteria that are subjective and as such do not have a grant date. The awards will be marked-to-market each reporting period during the performance period. The quantity of shares that will be issued upon vesting will range from 0% to 200% of the targeted number of shares; if the defined minimum targets are not met, then no shares will vest.

During fiscal year 2020, we awarded 8 PSUs (the "FY 20 PSUs") subject to both service and performance conditions to eligible employees. The FY 20 PSUs had a grant date fair value of $202.00 per share and vested during the six months ended September 30, 2022.  Based on actual performance targets achieved, the awards vested at 126% of target, resulting in a total of 10 awards distributed. 

Note 9. Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share (“diluted EPS”) is computed similarly to basic earnings (loss) per share, except that it includes the potential dilution that could occur if dilutive securities were exercised. Potentially dilutive securities include stock options and both time and performance based RSUs (collectively “stock awards”), as well as common shares underlying the Notes. Stock awards are excluded from the calculation of diluted EPS if they are subject to performance conditions that have not yet been achieved or are antidilutive. Diluted EPS considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would then have an antidilutive effect. There was no dilution in our diluted EPS calculation for the six months ended September 30, 2022 as we incurred a net loss and the effect would have been antidilutive.

The impact of the assumed conversion of the Notes calculated under the if-converted method was antidilutive, and as such, shares underlying the Notes were excluded from the diluted EPS calculation for the three and six months ended September 30, 2022 and September 30, 2021. 

Page 12

 

The following table presents a reconciliation of the denominators used in the computation of basic and diluted earnings (loss) per share:

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022			2021
Net income (loss) available for shareholders	$	1,306	$	3,720	$	(132	)	$	5,715
Weighted average outstanding shares of common stock		5,323		5,211		5,298			5,182
Dilutive effect of stock options		27		109		-			109
Dilutive effect of RSUs		14		24		-			33
Fully diluted shares		5,364		5,344		5,298			5,324
Basic earnings (loss) per share	$	0.25	$	0.71	$	(0.02	)	$	1.10
Diluted earnings (loss) per share	$	0.24	$	0.70	$	(0.02	)	$	1.07

The following stock awards were excluded from the calculation of diluted EPS:

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Assumed conversion of the Notes		608		608		608		608
Stock awards that were anti-dilutive		154		43		328		40
Stock awards subject to performance conditions		60		8		52		8
Total stock awards excluded from diluted EPS		822		659		988		656

Note 10. Income Taxes

For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year-to-date pre-tax income. Each quarter, our estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. Additionally, the tax effects of significant unusual or infrequently occurring items are recognized as discrete items in the interim period in which the events occur. There is a potential for volatility in the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, settlement with taxing authorities, and foreign currency fluctuations.

Our effective income tax rate was (93.5%) for the six months ended September 30, 2022, and 4.1% for the six months ended September 30, 2021. The effective tax rate for the six months ended September 30, 2022 differed from the statutory federal rate of 21% primarily due to the share-based payment awards for employees and the effect of income generated in foreign jurisdictions.  The effective tax rate for the first six months of 2023 was lower than the same period in 2022 primarily due to the share based compensation and the effect of income in foreign jurisdictions.

Note 11. Commitments and Contingencies

We review the adequacy of our legal reserves on a quarterly basis and establish reserves for loss contingencies that are both probable and reasonably estimable. As of September 30, 2022, there were no material legal reserves recorded on the accompanying unaudited Condensed Consolidated Balance Sheets. 

Page 13

  

Note 12. Segment Information

During fiscal year 2022, we realigned our financial reporting segments to reflect how management evaluates the business and allocates resources. The acquisition of Agena expanded our presence further into the life sciences tools market and provided an impetus for the creation of our new Clinical Genomics reportable segment. The strategic shift in our business also resulted in a change to the way we manage other business units, and as a result, our historical Instruments and Continuous Monitoring reportable segments have been combined to create Calibration Solutions. Prior year amounts presented have been reclassified to conform to current year presentation. Our change in financial reporting segments has not resulted in any change to previously reported consolidated amounts.

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Revenues:
Clinical Genomics	$	18,435		$	-		$	32,940		$	-
Sterilization and Disinfection Control		16,964			14,033			31,738			29,183
Biopharmaceutical Development		12,144			10,555			23,111			19,432
Calibration Solutions		11,206			11,252			21,413			22,145
Total revenues (a)	$	58,749		$	35,840		$	109,202		$	70,760
Gross profit
Clinical Genomics	$	10,641		$	-		$	18,490		$	-
Sterilization and Disinfection Control		12,199			10,486			22,967			21,914
Biopharmaceutical Development		7,557			6,601			14,634			11,293
Calibration Solutions		6,007			6,128			11,671			12,240
Reportable segment gross profit		36,404			23,215			67,762			45,447
Corporate and Other (b)		(18	)		(75	)		(35	)		(96	)
Gross profit	$	36,386		$	23,140		$	67,727		$	45,351
Reconciling Items:
Operating expenses		32,391			18,939			68,326			38,027
Operating income (loss)		3,995			4,201			(599	)		7,324
Nonoperating expense (income), net		611			(342	)		1,429			1,363
Earnings (loss) before income taxes	$	3,384		$	4,543		$	(2,028	)	$	5,961

^(a) Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

^(b) Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other. 

The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.

	September 30,		March 31,
	2022		2022
Clinical Genomics	$	12,600	$	11,802
Sterilization and Disinfection Control		2,864		2,176
Biopharmaceutical Development		5,214		4,495
Calibration Solutions		7,361		6,133
Total inventories	$	28,039	$	24,606

Page 14

  

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

(Dollars in thousands, except per share amounts)

Forward Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statements in this Quarterly Report on Form 10-Q do not constitute guarantees of future performance. Investors are cautioned that statements in this Quarterly Report on Form 10-Q which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position; potential impairment of future earnings; anticipated effects of, and future actions to be taken in response to, the COVID-19 pandemic; results of acquisitions; management’s strategy, plans and objectives for future operations or acquisitions, product development and sales; product research and development; regulatory approvals; selling, general and administrative expenditures; intellectual property; development and manufacturing plans; availability of materials and components; and adequacy of capital resources and financing plans constitute forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates, and management’s beliefs and assumptions. In addition, other written and oral statements that constitute forward-looking statements may be made by the Company or on the Company’s behalf. Words such as “expect,” “seek,” “intend,” “could,” “believe,” “may,” “anticipate,” “estimate,” “plan,” “target,” “project,” or variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks associated with: our ability to successfully grow our business, including as a result of acquisitions; the results that acquisitions have on our operations; our ability to consummate acquisitions at our historical rate and at appropriate prices, and our ability to effectively integrate acquired businesses and achieve desired results; the market acceptance of our products; technological or market viability of our products; reduced demand for our products, including as a result of competitive factors; conditions in the global economy and the particular markets we serve; significant developments or uncertainties stemming from governmental actions, including changes in trade policies and medical device regulations; the timely development and commercialization, and customer acceptance, of enhanced and new products and services; retirement of old products and customer migration to new products; projections of revenues, growth, operating results, profit margins, earnings, expenses, margins, tax rates, tax provisions, liquidity, cash flows, demand, and competition; the effects of additional actions taken to become more efficient or lower costs; the duration and impact of the COVID-19 pandemic and its adverse effects on our business; supply chain challenges; cost pressures and the overall effects of the current high inflation environment on customers’ purchasing patterns; laws regulating fraud and abuse in the health care industry and the privacy and security of health and personal information; product liability; information security; outstanding claims, legal and regulatory proceedings; international business challenges including anti-corruption and sanctions laws; tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; general economic, industry, and capital markets conditions, including rising interest rates and potential recessionary conditions; the timing of any of the foregoing; and assumptions underlying any of the foregoing. Such risks and uncertainties also include those listed in Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the year ended March 31, 2022 and in this report. The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. We disclaim any obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise.

Overview

We are a multinational manufacturer, developer, and seller of life science tools and quality control products and services, many of which are sold into niche markets that are driven by regulatory requirements. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe, and Asia Pacific, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins. 

As of September 30, 2022, we managed our operations in four reportable segments, or divisions: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Each of our divisions are described further in "Results of Operations" below. 

Corporate Strategy

We strive to create shareholder value and further our purpose of Protecting the Vulnerable^® by growing our business both organically and through acquisitions, by improving our operating efficiency, and by continuing to hire, develop and retain top talent. As a business, we commit to our purpose of Protecting the Vulnerable^® every day by taking a customer-focused approach to developing, building, and delivering our products. We serve a broad set of industries, in particular the pharmaceutical, healthcare services, and medical device verticals, in which the safety, quality, and efficacy of products is critical.  By delivering the highest quality products possible, we are committed to protecting people, the environment, and end products.

Organic Revenues Growth

Organic revenues growth is driven by the expansion of our customer base, increases in sales volumes, new product offerings, and price increases, and may be affected positively or negatively by changes in foreign currency rates. Our ability to increase organic revenues is affected by general economic conditions, both domestic and international, customer capital spending trends, competition, and the introduction of new products. Our policy is to price our products competitively and, where possible, we pass along cost increases to our customers in order to maintain our margins. We typically evaluate costs and pricing annually; however, as a result of high inflation in recent quarters, we increased prices late in the second quarter of fiscal year 2023, and we expect to realize these price increases beginning in the third quarter of fiscal year 2023.

Page 15

Inorganic Growth - Acquisitions

During the third quarter of fiscal year 2022, we completed the acquisition of Agena for an aggregate net purchase price of $300,793. Agena is a leading clinical genomics tools company that develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics and oncology related applications. The acquisition of Agena accelerated our strategic trajectory towards higher growth applications within the regulated segments of the life sciences tools market. 

Over the past decade, we have consummated a number of acquisitions as part of our growth strategy.  These acquisitions have allowed us to expand our product offerings, globalize our company, and increase the scale at which we operate, which in turn affords us the ability to improve our operating efficiency, extend our customer base, and further the pursuit of our purpose: Protecting the Vulnerable®.

Improving Our Operating Efficiency

We maximize value in both our existing businesses and those we acquire by implementing efficiencies in our manufacturing, commercial, engineering, and administrative operations. We achieve efficiencies using the four pillars that make up The Mesa Way, which is our customer-centric, lean-based system for continuously improving and operating a set of high-margin, niche businesses. The Mesa Way is focused on: Measuring What Matters using our customers' perspective and setting high standards for performance; Empowering Teams to improve operationally and exceed customer expectations; Steadily Improving using lean-based tools designed to help us identify the root cause of opportunities and prioritize the biggest opportunities; and Always Learning so that performance continuously improves. 

Gross profit is affected by many factors including our product mix, manufacturing efficiencies, costs of products and labor, foreign currency rates, and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross profit percentages for some products have improved. There are, however, differences in gross profit percentages between product lines, and ultimately the mix of sales will continue to impact our overall gross profit.

Hire, Develop, and Retain Top Talent

At the center of our organization are talented people who are capable of taking on new challenges using a team approach. It is our exceptionally talented workforce that works together and uses our lean-based tool set to find ways to continuously improve our products, our services, and ourselves, resulting in long-term value creation for our shareholders. 

General Trends

COVID-19 has caused or exacerbated broad market phenomena such as supply chain disruptions, inflation, and wage pressure to which we are susceptible. While supply chain constraints continue to impact all of our divisions, particularly our Calibration Solutions division, we expect that constraints will abate somewhat over the remainder of fiscal year 2023. We continue to work with our suppliers to understand the existing and potential future impacts to our supply chain and are taking actions in an effort to mitigate such impacts, including pre-ordering components in higher quantities than usual, which has resulted in increased raw materials balances on our consolidated balance sheets as of September 30, 2022. We have also experienced labor shortages and inflationary pressures due to labor market conditions, impacting all of our divisions, particularly our Sterilization and Disinfection Control division. 

Conditions related to the COVID-19 pandemic have continued to improve during the second quarter of our fiscal year 2023; however, there has been significant variation in business impact by geography. For example, late in fiscal year 2022 and continuing through May 2022, an increase in COVID-19 cases in certain parts of China resulted in the re-imposition of government mandated shut-downs and restrictions, which impacted our operations in China, particularly our Clinical Genomics division. Such regulatory restrictions negatively impacted commercial execution in the first quarter of fiscal year 2023, limiting sales of Clinical Genomics consumables to existing customers and instruments to new customers. During the second quarter of fiscal year 2023, China experienced additional intermittent shut-downs and restrictions; however, our operations were not significantly impacted. The extent to which these restrictions may recur in the future and the resulting impact to us will depend upon the prevalence of COVID-19 in the impacted regions of China. Even after the COVID-19 pandemic has largely subsided as a public health matter, we may experience material adverse impacts to our business as a result of the pandemic's adverse impact on the global economy, in-person collaboration and sales efforts, and our customers’ changed purchasing behaviors and confidence.

Currency exchange rates negatively impacted our reported sales for the three and six months ended September 30, 2022, primarily due to the strengthening of the U.S. dollar ("USD") against the euro, the Swedish Krona ("SEK") and the Chinese Yuan Renminbi.  Any further strengthening of the USD against major currencies would adversely impact our reported revenues, but would positively impact our expenses for the remainder of the fiscal year, and any weakening of the U.S. dollar against major currencies would positively impact our reported revenues but would negatively impact our expenses for the remainder of the fiscal year.

Results of Operations

Our results of operations and period-over-period changes are discussed in the following section. The tables and discussion below should be read in conjunction with the accompanying Unaudited Condensed Consolidated Financial Statements and the notes thereto appearing in Item 1. Financial Statements (in thousands, except percent data).

Revenues from our reportable segments increased 64% and 54% for the three and six months ended September 30, 2022, respectively, compared to the relevant prior year period. Revenues growth was primarily attributable to the acquisition of Agena; however, organic revenues growth was 12% and 8% for the three and six months ended September 30, 2022, respectively. Gross profit as a percentage of revenues decreased three percentage and two percentage points for the three and six months ended September 30, 2022, respectively, compared to the three and six months ended September 30, 2021, primarily as a result of foreign currency impacts on revenues, inflationary pressures, continued supply chain constraints, and product mix. Results by reportable segment are as follows:

	Revenues				Organic Revenues Growth						Gross Profit as a % of Revenues
	Three Months Ended September 30, 2022		Three Months Ended September 30, 2021		Three Months Ended September 30, 2022			Three Months Ended September 30, 2021			Three Months Ended September 30, 2022			Three Months Ended September 30, 2021
Clinical Genomics (*)	$	18,435	$	-		N/A			N/A			58	%		N/A
Sterilization and Disinfection Control		16,964		14,033		21	%		21	%		72	%		75	%
Biopharmaceutical Development		12,144		10,555		15	%		16	%		62	%		63	%
Calibration Solutions		11,206		11,252		-	%		1	%		54	%		54	%
Mesa's reportable segments	$	58,749	$	35,840		12	%		12	%		62	%		65	%

	Revenues				Organic Revenues Growth						Gross Profit as a % of Revenues
	Six Months Ended September 30, 2022		Six Months Ended September 30, 2021		Six Months Ended September 30, 2022			Six Months Ended September 30, 2021			Six Months Ended September 30, 2022			Six Months Ended September 30, 2021
Clinical Genomics (*)	$	32,940	$	-		N/A			N/A			56	%		N/A
Sterilization and Disinfection Control		31,738		29,183		9	%		19	%		72	%		75	%
Biopharmaceutical Development		23,111		19,432		19	%		29	%		63	%		58	%
Calibration Solutions		21,413		22,145		(3	%)		0	%		55	%		55	%
Mesa's reportable segments	$	109,202	$	70,760		8	%		14	%		62	%		64	%

(*) Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021. 

Page 16

Our unaudited condensed consolidated results of operations are as follows:

	Three Months Ended September 30,				Percentage			Six Months Ended September 30,					Percentage
	2022		2021		Change			2022			2021		Change
Revenues	$	58,749	$	35,840		64	%	$	109,202		$	70,760		54	%
Gross profit		36,386		23,140		57	%		67,727			45,351		49	%
Operating expenses		32,391		18,939		71	%		68,326			38,027		80	%
Operating income (loss)		3,995		4,201		(5	%)		(599	)		7,324		(108	%)
Net income (loss)	$	1,306	$	3,720		(65	%)	$	(132	)	$	5,715		(102	%)

Reportable Segments

Clinical Genomics

The Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics and oncology related applications.

	Three Months Ended September 30,					Percentage		Six Months Ended September 30,					Percentage
	2022			2021		Change		2022			2021		Change
Revenues	$	18,435		$	-		N/A	$	32,940		$	-		N/A
Gross profit		10,641			-		N/A		18,490			-		N/A
Gross profit as a % of revenues		58	%		N/A		N/A		56	%		N/A		N/A

Revenues for the Clinical Genomics division were $18,435 for the second quarter of fiscal year 2023. China’s government-mandated shutdowns and restrictions in response to the COVID-19 pandemic were largely lifted beginning in May 2022, and as a result, revenues in the Clinical Genomics division reached a more normal level in the second quarter of fiscal year 2023. Of the revenues reported, $179 represent revenues from COVID-19 related sales. Revenues in the Clinical Genomics division for the second quarter of fiscal year 2023 represented an increase of 27% compared to the first quarter of fiscal year 2023.

Revenues for the Clinical Genomics division were $32,940 for the six months ended September 30, 2022. Revenues were negatively impacted by China's government-mandated shutdowns, which began in late fiscal year 2022 and continued through May 2022. These restrictions negatively impacted commercial execution in the first quarter of fiscal year 2023, limiting sales of Clinical Genomics consumables to existing customers and instruments to new customers. Of the revenues reported in the current year period, $374 represent revenues from COVID-19 related sales. 

Gross profit for the Clinical Genomics division was $10,641 and $18,490 for the three and six months ended September 30, 2022, respectively. Gross profit as a percentage of revenues for the three months ended September 30, 2022 benefitted from higher revenues to cover a partially-fixed cost base. Gross profit percentage of revenues for the six months ended September 30, 2022 benefitted from higher revenues in the second quarter of fiscal year 2023, partially offset by the negative impact of China's government-mandated shutdowns in the beginning of the first quarter of fiscal year 2023.

Sterilization and Disinfection Control

Our Sterilization and Disinfection Control division manufactures and sells biological, cleaning, and chemical indicators which are used to assess the effectiveness of sterilization and disinfection processes in the hospital, medical device, and pharmaceutical industries. The division also provides testing and laboratory services, mainly to the dental industry. Sterilization and disinfection control products are disposable and are used on a routine basis.

	Three Months Ended September 30,						Percentage			Six Months Ended September 30,						Percentage
	2022			2021			Change			2022			2021			Change
Revenues	$	16,964		$	14,033			21	%	$	31,738		$	29,183			9	%
Gross profit		12,199			10,486			16	%		22,967			21,914			5	%
Gross profit as a % of revenues		72	%		75	%		(3	%)		72	%		75	%		(3	%)

Sterilization and Disinfection Control revenues increased 21% and 9% for the three and six months ended September 30, 2022, respectively, compared to the relevant prior year periods, despite a significant strengthening of the USD against the euro. During the second quarter of fiscal year 2023, we added temporary and permanent manufacturing headcount at our Bozeman Montana facility, which enabled us to fulfill a higher volume of customer orders compared to the three months ended June 30, 2022. While we were able add capacity to our manufacturing workforce during the second quarter of fiscal year 2023, it is possible that this division will experience labor shortages in the future which could impact the division's gross profits. The three and six months ended September 30, 2022 also benefited from favorable product mix and to a lesser extent, price increases. 

Sterilization and Disinfection Control's gross profit percentage decreased three percentage points for the three and six months ended September 30, 2022 compared to the relevant prior year periods as a result of foreign currency fluctuations negatively impacting our reported revenues, and increased labor and labor-related costs.

Biopharmaceutical Development

Our Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufacture of biotherapeutic drugs. 

	Three Months Ended September 30,						Percentage			Six Months Ended September 30,						Percentage
	2022			2021			Change			2022			2021			Change
Revenues	$	12,144		$	10,555			15	%	$	23,111		$	19,432			19	%
Gross profit		7,557			6,601			14	%		14,634			11,293			30	%
Gross profit as a % of revenues		62	%		63	%		(1	%)		63	%		58	%		5	%

Biopharmaceutical Development revenues increased 15% and 19% for the three and six months ended September 30, 2022, respectively, compared to the relevant prior year periods, primarily due to increased product adoption, and price increases, partially offset by unfavorable changes in foreign currency exchange rates. The increase for the six months ended September 30, 2022 resulted in part from the fact that some COVID-19 related restrictions were still in place during the first quarter of fiscal year 2022.  Increases in revenues were partially offset by unfavorable changes in foreign exchange rates.

Page 17

Biopharmaceutical Development's gross profit percentage decreased one percentage point for the three months ended September 30, 2022 compared to the three months ended September 30, 2021 as a result of foreign currency impacts, unfavorable product mix and higher labor and materials costs. Biopharmaceutical Development's gross profit percentage increased five percentage points for the six months ended September 30, 2022 compared to the six months ended September 30, 2021 as a result of higher revenues on a partially-fixed cost base, partially offset by foreign currency impacts.

Calibration Solutions

The Calibration Solutions division designs, manufactures, and markets quality control and calibration products used to measure or calibrate temperature, pressure, pH, humidity, and other chemical or physical parameters for health and safety purposes, primarily in hospital, medical device manufacturing, pharmaceutical, and laboratory environments.

	Three Months Ended September 30,						Percentage			Six Months Ended September 30,						Percentage
	2022			2021			Change			2022			2021			Change
Revenues	$	11,206		$	11,252			-	%	$	21,413		$	22,145			(3	%)
Gross profit		6,007			6,128			(2	%)		11,671			12,240			(5	%)
Gross profit as a % of revenues		54	%		54	%		-	%		55	%		55	%		-	%

Calibration Solutions revenues were essentially flat for the three months ended September 30, 2022 relative to the prior year period, primarily due to our ability to overcome certain global supply chain issues which allowed us to begin to fill previously-backlogged orders in certain of our product classes. During the six months ended September 30, 2022, revenues decreased 3% compared to the prior year period primarily as a result of supply constraints limiting our ability to manufacture ordered quantities of certain products.

Calibration Solutions' gross profit percentage was essentially flat for the three and six months ended September 30, 2022 as compared to the three and six months ended September 30, 2021.

Operating Expenses

Operating expenses increased 71% and 80% for the three and six months ended September 30, 2022, respectively, compared to the three and six months ended September 30, 2021 primarily as a result of the Agena Acquisition and as our overall business grew. Operating expenses were favorably impacted by the strengthening of the USD during the three and six months ended September 30, 2022. 

Selling

Selling expense is driven primarily by labor costs, including salaries and commissions; accordingly, it may vary with sales levels.

	Three Months Ended September 30,						Percentage			Six Months Ended September 30,						Percentage
	2022			2021			Change			2022			2021			Change
Selling expense	$	9,200		$	4,643			98	%	$	19,223		$	9,501			102	%
As a percentage of revenues		16	%		13	%		3	%		18	%		13	%		5	%

Selling expense for the three and six months ended September 30, 2022 increased 98% and 102%, respectively, compared to the relevant prior year periods, primarily as a result of the acquisition of Agena. Excluding Agena, selling expense increased 15% and 16% for the three and six months ended September 30, 2022, respectively, primarily as a result of increased travel and tradeshow costs as we continued to resume in-person meetings and events, as well as higher professional services costs as we made improvements to our corporate website.

General and Administrative

Labor costs, including non-cash stock-based compensation, and amortization of intangible assets drive the substantial majority of our general and administrative expense.

	Three Months Ended September 30,						Percentage			Six Months Ended September 30,						Percentage
	2022			2021			Change			2022			2021			Change
General and administrative expense	$	18,202		$	11,683			56	%	$	38,414		$	23,102			66	%
As a percentage of revenues		31	%		33	%		(2	%)		35	%		33	%		2	%

General and administrative expenses increased 56% and 66% for the three and six months ended September 30, 2022, respectively, compared to the relevant prior year periods, primarily as a result of the Agena Acquisition.  Included in both increases is the amortization of intangible assets associated with the Agena acquisition of $2,398 and $4,888 for the three and six months ended September 30, 2022, respectively. Excluding Agena, general and administrative expense increased 15% and 24% for the three and six months ended September 30, 2022, respectively primarily as a result of higher stock-based compensation expense, and to a lesser extent, increased labor and labor related expenses and Agena integration expenses, partially offset by lower amortization expense due to favorable currency exchange rates.

Page 18

Research and Development

Research and development expense is predominantly comprised of labor costs and costs of third-party consultants.

	Three Months Ended September 30,						Percentage			Six Months Ended September 30,						Percentage
	2022			2021			Change			2022			2021			Change
Research and development expense	$	4,989		$	2,613			91	%	$	10,689		$	5,424			97	%
As a percentage of revenues		8	%		7	%		1	%		10	%		8	%		2	%

Research and development expenses increased 91% and 97% for the three and six months ended September 30, 2022, respectively, relative to the relevant prior year periods, primarily as a result of the acquisition of Agena. Excluding the impact of Agena, research and development costs for the three months ended September 30, 2022 increased 2% relative to the prior year period primarily due to increased labor and labor related costs. For the six months ended September 30, 2022, research and development costs increased 13% excluding the impact of Agena, primarily as a result of our purchase of in process research and development technology that we intend to further develop in order to enhance a product offering in our Sterilization and Disinfection Control division.

Nonoperating Expense 

	Three Months Ended September 30,					Percentage			Six Months Ended September 30,				Percentage
	2022		2021			Change			2022		2021		Change
Nonoperating expense (income)	$	611		(342	)		(279	%)	$	1,429	$	1,363		5	%

Nonoperating expense for the three and six months ended September 30, 2022 is composed primarily of interest expense and amortization of the debt discount associated with the Notes and the Credit Facility as well as gains and losses on foreign currency transactions. Nonoperating expense was higher during the three and six months ended September 30, 2022 compared to the three and six months ended September 30, 2021 due to interest expense on the Credit Facility, which had an average balance of $38,000 during the six months ended September 30, 2022 compared with no balance throughout the first six months of fiscal year 2022. In addition, we recorded net foreign currency gains in the three and six months ended September 30, 2021. 

Income Taxes

	Three Months Ended September 30,						Percentage			Six Months Ended September 30,						Percentage
	2022			2021			Change			2022			2021			Change
Income tax provision (benefit)	$	2,078		$	823			152	%	$	(1,896	)	$	246			(871	%)
Effective tax rate		61.4	%		18.1	%		43	%		93.5	%		4.1	%		89	%

Our effective income tax rate was 61.4% and (93.5%) for the three and six months ended September 30, 2022, respectively, and 18.1% and 4.1% for the three and six months ended September 30, 2021, respectively. The effective tax rate for the six months ended September 30, 2022 differed from the statutory federal rate of 21% primarily due to the share-based payment awards for employees and the effect of income generated in foreign jurisdictions. The effective tax rate for the six months ended September 30, 2022 was lower than the same period in 2022 primarily due to the share-based compensation and the effect of income in foreign jurisdictions.

Our future effective income tax rate depends on various factors, such as changes in tax laws, regulations, accounting principles, or interpretations thereof, and the geographic composition of our pre-tax income. We carefully monitor these factors and adjust our effective income tax rate accordingly. 

Net Income (Loss) 

Net income (loss) varies with changes in revenues, gross profit, and operating expenses (and included $14,426 and $7,803 of non-cash amortization of intangible assets acquired in business combinations and stock-based compensation expense, respectively, for the six months ended September 30, 2022).

Liquidity and Capital Resources

Our sources of liquidity include cash generated from operations, cash and cash equivalents on hand, cash available from our Credit Facility and the Open Market Sale Agreement^SM, described below, working capital, and potential additional equity and debt offerings.  We believe that cash flows from operating activities and potential cash provided by borrowings from our Credit Facility or funds from our Open Market Sale Agreement^SM, when necessary, will be sufficient to meet our ongoing operating requirements, scheduled interest payments on debt, dividend payments, and anticipated capital expenditures. We currently expect to settle the Notes in shares of our common stock, but we may re-finance the debt, depending on conditions in the market and the share price of our common stock. 

Our more significant uses of resources have historically included acquisitions, payments of debt and interest obligations, long-term capital expenditures, and quarterly dividends to shareholders. Working capital is the amount by which current assets exceed current liabilities. We had working capital of $74,754 and $76,263 as of September 30, 2022 and March 31, 2022, respectively. As of September 30, 2022, and March 31, 2022, we had $32,377 and $49,346, respectively, of cash and cash equivalents. We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

As of September 30, 2022, $172,500 in aggregate principal Notes was outstanding and $27,000 was outstanding under the Credit Facility. In October 2022, we repaid $2,000 of the amount outstanding under the Credit Facility.

In April 2022, we entered into an Open Market Sale Agreement^SM pursuant to which we may issue and sell, from time to time, shares of our common stock with an aggregate value of up to $150 million.

We routinely evaluate opportunities for strategic acquisitions. Future material acquisitions may require that we obtain additional capital, assume additional third-party debt or incur other long-term obligations. We believe that we have the ability to issue more equity or debt in the future in order to finance our acquisition and investment activities; however, additional equity or debt financing, or other transactions, may not be available on acceptable terms, if at all.

We may from time to time repurchase or take other steps to reduce our debt. These actions may include retirements or refinancing of outstanding debt, privately negotiated transactions or otherwise. The amount of debt that may be retired, if any, could be material and would be decided at the sole discretion of our Board of Directors and would depend on market conditions, our cash position, and other considerations.

Page 19

Dividends

We have paid regular quarterly dividends since 2003. We declared and paid dividends of $0.16 per share during each of the quarters ended June 30, 2022 and September 30, 2022, as well as each quarter of fiscal year 2022.

In October 2022, we announced that our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on December 15, 2022, to shareholders of record at the close of business on November 30, 2022.

Cash Flows

Our cash flows from operating, investing, and financing activities were as follows (in thousands):

	Six Months Ended September 30,
	2022			2021
Net cash provided by operating activities	$	7,746		$	14,023
Net cash (used in) investing activities		(1,864	)		(1,591	)
Net cash (used in) provided by financing activities		(20,053	)		1,423

Cash flows from operating activities for the six months ended September 30, 2022 provided $7,746. Net loss, and non cash adjustments totaled $22,768 for the six months ended September 30, 2022 compared to $19,019 for the six months ended September 30, 2021. Adjustments to working capital accounts used $10,026 more cash in the six months ended September 30, 2022 compared to the six months ended September 30, 2021, primarily due to lower collections on trade receivables and higher spend on inventory as we built supplies to mitigate supply chain risk. Cash used in investing activities was higher during the six months ended September 30, 2022 compared to the six months ended September 30, 2021, due to increased purchases of property, plant, and equipment as we completed the renovation of our Lakewood, Colorado manufacturing facility during fiscal year 2023. Cash used by financing activities primarily resulted from $22,000 repaid on our Credit Facility during the six months ended September 30, 2022.

Contractual Obligations and Other Commercial Commitments

We are party to many contractual obligations that involve commitments to make payments to third parties in the ordinary course of business. For a description of our contractual obligations and other commercial commitments as of March 31, 2022, see our Annual Report on Form 10-K for the fiscal year ended March 31, 2022, filed with the Securities and Exchange Commission on May 31, 2022.  

On a consolidated basis, as of September 30, 2022, we had contractual obligations for open purchase orders of approximately $24,331 for routine purchases of supplies and inventory, which are payable in less than one year. Open purchase orders continue to increase as we take proactive steps to mitigate risks in supply by increasing our orders of certain critical raw materials. 

Critical Accounting Policies and Estimates

Critical accounting estimates are those that we believe are both significant and require us to make difficult, subjective, or complex judgments, often because we need to estimate the effect of inherently uncertain matters. These estimates are based on historical experience and various other factors that we believe to be appropriate under the circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2022, in the Critical Accounting Policies and Estimates section of Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Our reporting currency is U.S. dollars, and the functional currency of each of our material foreign subsidiaries is its respective local currency. Our operations include activities outside of the U.S. and we have currency risk on the transactions in other currencies and translation adjustments resulting from the conversion of our international financial results into the U.S. dollar. We face currency exposures in our global operations as a result of various factors including intercompany currency denominated loans, selling our products in various currencies, purchasing raw materials and equipment in various currencies, and tax exposures not denominated in the functional currency. These exposures have increased as we have continued to expand internationally, including the acquisition of Gyros Protein Technologies Holding AB, which incurs a substantial portion of its business expenses in Swedish Krona, and the acquisition of Agena, which conducts a portion of its business in euros and a portion in Chinese Yuan Renminbi. Fluctuations in exchange rates have and may continue to adversely affect our results of operations, financial position, and cash flows. We do not hedge exposure to exchange rates.

Our Credit Facility bears interest at either a base rate or a Eurodollar rate, plus an applicable spread. Based on the balance currently outstanding against our line of credit, if interest rates increased by 75 basis points, we would incur approximately $203 of additional interest expense per year. 

We have no derivative instruments. We have minimal exposure to commodity market risks.

Page 20

Item 4. Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) promulgated under the Exchange Act) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures

As of September 30, 2022, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control over Financial Reporting

The Agena Acquisition was completed on October 20, 2021, and the financial results of Agena are included in our Condensed Consolidated Financial Statements as of March 31, 2022 and for the period then ended, and as of September 30, 2022 and for the six months then ended. During the time since acquisition, we have assessed the control environment of Agena and made certain changes to Agena's internal controls over financial reporting, including design changes that were required as we brought Agena onto our enterprise resource planning tool. We now consider Agena to be included in the scope of our assessment of internal controls over financial reporting. 

Page 21

Part II. Other Information

Item 1. Legal Proceedings

See Note 11. “Commitments and Contingencies” within Item 1. Financial Statements for information regarding any legal proceedings in which we may be involved.

Item 1A. Risk factors

During the first and second quarters of fiscal year 2023, there were no material changes from the risk factors described in Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended March 31, 2022. 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

The following table provides information about the Company's purchases of equity securities for the periods indicated:

	Total Number of Shares Purchased(1)		Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(2)		Maximum Number of Shares That May Yet be Purchased Under the Plans or Programs
July 2022		1,097		203.83		-		162,486
August 2022		-		-		-		162,486
September 2022		1,954		178.42		-		162,486
Total		3,051		187.56		-		162,486

⁽¹⁾ Shares purchased during the period were transferred to the Company from employees in satisfaction of minimum tax withholding obligations associated with the vesting of restricted stock awards during the period.

⁽²⁾ On November 7, 2005, our Board of Directors adopted a share repurchase plan which allows for the repurchase of up to 300,000 of our common shares; however, no shares have been purchased under the plan in the last three fiscal years. This plan will continue until the maximum is reached or the plan is terminated by further action of the Board of Directors.  

Page 22

Item 6. Exhibits

Exhibit No.	Description of Exhibit
3.1	Articles of Incorporation and Amendments to Articles of Incorporation (incorporated by reference from exhibit 3.1 to Mesa Laboratories, Inc.’s report on Form 10-Q filed on July 31, 2018 (Commission File Number: 000-11740)).
3.2	Amended and Restated Bylaws of Mesa Laboratories, Inc. (incorporated by reference from exhibit 3.1 to the Current Report on Form 8-K filed on May 10, 2019 (Commission File Number: 000-11740)).
31.1+	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2+	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*	Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS+	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH+	Inline XBRL Taxonomy Extension Schema Document.
101.CAL+	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+	Inline XBRL Taxonomy Extension Definitions Linkbase Document
101.LAB+	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE+	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104+	Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*).

+ Filed herewith

* Furnished herewith

Page 23

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MESA LABORATORIES, INC.

(Registrant)

DATED: November 3, 2022	BY:	/s/ Gary M. Owens. Gary M. Owens Chief Executive Officer
DATED: November 3, 2022	BY:	/s/ John V. Sakys John V. Sakys Chief Financial Officer

Page 24

EX-31.1

Exhibit 31.1 Certifications Pursuant to Rule 13a-14(a)

I, Gary M. Owens, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Mesa Laboratories, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 3, 2022  /s/ Gary M. Owens Gary M. Owens Chief Executive Officer

EX-31.2

Exhibit 31.2 Certifications Pursuant to Rule 13a-14(a)

I, John V. Sakys, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Mesa Laboratories, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 3, 2022 /s/ John V. Sakys John V. Sakys Chief Financial Officer

EX-32.1

Exhibit 32.1 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350

In connection with the Quarterly Report of Mesa Laboratories, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended September 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gary M. Owens, Chief Executive Officer of the Company, certify, pursuant to Rule 13a-14(b) and 18 U.S.C. § 1350, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 3, 2022 /s/ Gary M. Owens Gary M. Owens Chief Executive Officer

EX-32.2

Exhibit 32.2 Certifications Pursuant to Rule 13a-14(b) and 18 U.S.C Section 1350

In connection with the Quarterly Report of Mesa Laboratories, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended September 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John V. Sakys, Chief Financial Officer of the Company, certify, pursuant to Rule 13a-14(b) and 18 U.S.C. § 1350, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 3, 2022 /s/ John V. Sakys John V. Sakys Chief Financial Officer

XML

Document And Entity Information - shares	6 Months Ended
	Sep. 30, 2022	Oct. 27, 2022
Document Information [Line Items]
Entity Central Index Key	0000724004
Entity Registrant Name	MESA LABORATORIES INC /CO
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	0-11740
Entity Incorporation, State or Country Code	CO
Entity Tax Identification Number	84-0872291
Entity Address, Address Line One	12100 West Sixth Avenue
Entity Address, City or Town	Lakewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80228
City Area Code	303
Local Phone Number	987-8000
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	MLAB
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,336,807

XML

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Cash and cash equivalents	$ 32,377	$ 49,346
Accounts receivable, less allowance for doubtful accounts of $1,013 and $630, respectively	41,809	41,224
Inventories	28,039	24,606
Prepaid expenses and other	14,035	9,142
Total current assets	116,260	124,318
Property, plant and equipment, net of accumulated depreciation of $18,826 and $17,726, respectively	28,222	28,620
Deferred tax asset	647	1,318
Other assets	10,825	11,830
Intangibles, net	222,271	250,117
Goodwill	278,006	291,166
Total assets	656,231	707,369
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	7,738	7,897
Accrued payroll and benefits	7,481	14,717
Unearned revenues	13,831	13,830
Other accrued expenses	12,456	11,611
Total current liabilities	41,506	48,055
Deferred tax liability	36,847	39,224
Other long-term liabilities	6,826	7,924
Credit Facility	27,000	49,000
Convertible senior notes, net of discounts and debt issuance costs	169,816	169,365
Total liabilities	281,995	313,568
Stockholders’ equity:
Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,336,271 and 5,265,627 shares, respectively	324,905	313,460
Retained earnings	74,848	76,675
Accumulated other comprehensive (loss) income	(25,517)	3,666
Total stockholders’ equity	374,236	393,801
Total liabilities and stockholders’ equity	$ 656,231	$ 707,369

XML

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ / shares in Thousands, $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Allowance for doubtful accounts receivable	$ 1,013	$ 630
Property, plant and equipment, accumulated Depreciation	$ 18,826	$ 17,726
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	25,000,000	25,000,000
Common stock, shares issued (in shares)	5,336,271	5,265,627
Common stock, shares outstanding (in shares)	5,336,271	5,265,627

XML

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues	$ 58,749	$ 35,840	$ 109,202	$ 70,760
Cost of revenues	22,363	12,700	41,475	25,409
Gross profit	36,386	23,140	67,727	45,351
Operating expenses:
Selling	9,200	4,643	19,223	9,501
General and administrative	18,202	11,683	38,414	23,102
Research and development	4,989	2,613	10,689	5,424
Total operating expenses	32,391	18,939	68,326	38,027
Operating income (loss)	3,995	4,201	(599)	7,324
Nonoperating expense (income):
Interest expense and amortization of debt discount	1,214	815	2,228	1,629
Other (income), net	(603)	(1,157)	(799)	(266)
Total nonoperating expense (income)	611	(342)	1,429	1,363
Earnings (loss) before income taxes	3,384	4,543	(2,028)	5,961
Income tax provision (benefit)	2,078	823	(1,896)	246
Net income (loss)	$ 1,306	$ 3,720	$ (132)	$ 5,715
Earnings (loss) per share:
Basic earnings (loss) per share (in dollars per share)	$ 0.25	$ 0.71	$ (0.02)	$ 1.10
Diluted earnings (loss) per share (in dollars per share)	$ 0.24	$ 0.70	$ (0.02)	$ 1.07
Weighted-average common shares outstanding:
Basic (in shares)	5,323	5,211	5,298	5,182
Diluted (in shares)	5,364	5,344	5,298	5,324
Product [Member]
Revenues	$ 58,749	$ 35,840	$ 109,202	$ 70,760

XML

Condensed Consolidated Statements of Comprehensive (Loss) Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net (loss) income	$ 1,306	$ 3,720	$ (132)	$ 5,715
Other comprehensive (loss) income:
Foreign currency translation	(13,226)	(6,503)	(29,183)	(1,132)
Comprehensive (loss) income	$ (11,920)	$ (2,783)	$ (29,315)	$ 4,583

XML

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net (loss) income	$ (132)	$ 5,715
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	16,189	8,849
Stock-based compensation expense	7,803	4,236
Non-cash interest and debt amortization	452	443
Deferred taxes	(908)
Other	(636)	(224)
Cash (used in) provided by changes in operating assets and liabilities:
Accounts receivable, net	(2,657)	1,065
Inventories	(4,065)	(808)
Prepaid expenses and other assets	(3,052)	(1,473)
Accounts payable	243	(167)
Accrued liabilities and taxes payable	(5,869)	(4,596)
Unearned revenues	378	983
Net cash provided by operating activities	7,746	14,023
Cash flows from investing activities:
Purchases of property, plant and equipment	(1,864)	(1,591)
Net cash (used in) investing activities	(1,864)	(1,591)
Cash flows from financing activities:
Payments of debt	(22,000)	0
Dividends	(1,695)	(1,658)
Proceeds from the exercise of stock options	3,642	3,081
Net cash (used in) provided by financing activities	(20,053)	1,423
Effect of exchange rate changes on cash and cash equivalents	(2,798)	574
Net (decrease) increase in cash and cash equivalents	(16,969)	14,429
Cash and cash equivalents at beginning of period	49,346	263,865
Cash and cash equivalents at end of period	$ 32,377	$ 278,294

XML

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Cumulative Effect, Period of Adoption, Adjustment [Member] Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member] Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]		Total
Balance (in shares) at Mar. 31, 2021				5,140,568
Balance at Mar. 31, 2021				$ 317,652	$ 72,459	$ 16,116	[1]	$ 406,227
Exercise of stock options and vesting of restricted stock units (in shares)				58,324
Exercise of stock options and vesting of restricted stock units				$ 1,089				1,089
Dividends paid					(824)			(824)
Stock-based compensation expense				$ 2,197				2,197
Foreign currency translation						5,371	[1]	5,371
Foreign currency translation						5,371	[1]	5,371
Net (loss) income					1,995			1,995
Balance (in shares) at Jun. 30, 2021				5,198,892
Balance at Jun. 30, 2021	$ (22,735)	$ 5,683	$ (17,052)	$ 298,203	79,313	21,487	[1]	399,003
Balance (in shares) at Mar. 31, 2021				5,140,568
Balance at Mar. 31, 2021				$ 317,652	72,459	16,116	[1]	406,227
Foreign currency translation								(1,132)
Net (loss) income								5,715
Foreign currency translation								(1,132)
Net (loss) income								5,715
Balance (in shares) at Sep. 30, 2021				5,223,232
Balance at Sep. 30, 2021				$ 302,234	82,199	14,984	[1]	399,417
Balance (in shares) at Jun. 30, 2021				5,198,892
Balance at Jun. 30, 2021	$ (22,735)	$ 5,683	$ (17,052)	$ 298,203	79,313	21,487	[1]	399,003
Exercise of stock options and vesting of restricted stock units (in shares)				24,340
Exercise of stock options and vesting of restricted stock units				$ 1,992				1,992
Dividends paid					(834)			(834)
Stock-based compensation expense				$ 2,039				2,039
Foreign currency translation						(6,503)		(6,503)
Net (loss) income								3,720
Foreign currency translation						(6,503)		(6,503)
Net (loss) income					3,720			3,720
Balance (in shares) at Sep. 30, 2021				5,223,232
Balance at Sep. 30, 2021				$ 302,234	82,199	14,984	[1]	$ 399,417
Balance (in shares) at Mar. 31, 2022				5,265,627				5,265,627
Balance at Mar. 31, 2022				$ 313,460	76,675	3,666	[1]	$ 393,801
Exercise of stock options and vesting of restricted stock units (in shares)				31,681				42,000
Exercise of stock options and vesting of restricted stock units				$ 1,436				$ 1,436
Dividends paid					(843)			(843)
Stock-based compensation expense				$ 3,432				3,432
Foreign currency translation						(15,957)	[1]	(15,957)
Net (loss) income					(1,438)			(1,438)
Foreign currency translation						(15,957)	[1]	(15,957)
Balance (in shares) at Jun. 30, 2022				5,297,308
Balance at Jun. 30, 2022				$ 318,328	74,394	(12,291)	[1]	$ 380,431
Balance (in shares) at Mar. 31, 2022				5,265,627				5,265,627
Balance at Mar. 31, 2022				$ 313,460	76,675	3,666	[1]	$ 393,801
Foreign currency translation								(29,183)
Net (loss) income								(132)
Foreign currency translation								(29,183)
Net (loss) income								$ (132)
Balance (in shares) at Sep. 30, 2022				5,336,271				5,336,271
Balance at Sep. 30, 2022				$ 324,905	74,848	(25,517)	[1]	$ 374,236
Balance (in shares) at Jun. 30, 2022				5,297,308
Balance at Jun. 30, 2022				$ 318,328	74,394	(12,291)	[1]	380,431
Exercise of stock options and vesting of restricted stock units (in shares)				38,963
Exercise of stock options and vesting of restricted stock units				$ 2,206				2,206
Dividends paid					(852)			(852)
Stock-based compensation expense				4,371				4,371
Foreign currency translation						(13,226)		(13,226)
Net (loss) income				$ 0	1,306	0		1,306
Foreign currency translation						(13,226)		(13,226)
Net (loss) income								$ 1,306
Balance (in shares) at Sep. 30, 2022				5,336,271				5,336,271
Balance at Sep. 30, 2022				$ 324,905	$ 74,848	$ (25,517)	[1]	$ 374,236

[1] Accumulated Other Comprehensive Income (Loss).

XML

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Jun. 30, 2021
Dividends paid, per share (in dollars per share)	$ 0.16	$ 0.16	$ 0.16	$ 0.16

XML

Note 1 - Description of Business and Summary of Significant Accounting Policies

6 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]

Note 1. Description of Business and Summary of Significant Accounting Policies

Description of Business

In this quarterly report on Form 10-Q, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries is collectively referred to as “we,” “us,” “our,” the “Company” or “Mesa.”

We are a multinational manufacturer, developer, and seller of life science tools and critical quality control products and services, many of which are sold into niche markets that are driven by regulatory requirements. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe, and Asia Pacific, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins.

As of September 30, 2022, we managed our operations in four reportable segments, or divisions:

● Clinical Genomics - develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics and oncology related applications.

● Sterilization and Disinfection Control - manufactures and sells biological, cleaning, and chemical indicators which are used to assess the effectiveness of sterilization and disinfection processes in the hospital, medical device, and pharmaceutical industries. The division also provides testing and laboratory services, mainly to the dental industry. 

● Biopharmaceutical Development - develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufacture of biotherapeutic drugs. 

● Calibration Solutions - develops, manufactures, and sells quality control and calibration products used to measure or calibrate temperature, pressure, pH, humidity, and other chemical or physical parameters for health and safety purposes, primarily in hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. 

Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for the fair statement of our financial position and results of operations. The results of operations for the interim periods are not necessarily indicative of results that may be achieved for the entire year. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. We made no material changes to the application of our significant accounting policies that were disclosed in our Form 10-K. This quarterly report should be read in conjunction with the consolidated financial statements included in our annual report on Form 10-K for the year ended  March 31, 2022.

Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year, references to the first quarter of fiscal year 2023 refer to the period from April 1, 2022 through June 30, 2022, and references to the second quarter of fiscal year 2023 refer to the period from July 1, 2022 through September 30, 2022. References to “fiscal year 2022” refer to the fiscal year ended March 31, 2022, and to “fiscal year 2023” refer to the fiscal year ending March 31, 2023.

Prior Period Reclassification

Certain amounts presented for prior periods related to the Biopharmaceutical Development division in Note 3. "Revenue Recognition" have been reclassified out of revenues from consumables and into revenues from hardware and services. These reclassifications have not resulted in any change to the Condensed Consolidated Financial Statements for and periods presented in this Form 10-Q.

Risks and Uncertainties

The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgement about the outcome of future events. The business and economic uncertainty resulting from the novel coronavirus pandemic ("COVID-19"), supply chain challenges, cost pressure and the overall effects of the current high inflation environment on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates.

Recently Issued Accounting Pronouncements

We have reviewed all recently issued accounting pronouncements and have concluded that they are either not applicable to us or are not expected to have a significant impact on our consolidated financial statements.

XML

Note 2 - Significant Transactions

6 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Significant Transactions [Text Block]

Note 2. Significant Transactions

On October 20, 2021, we completed the acquisition of Agena Bioscience, Inc. (“Agena”) for $300,793, net of cash acquired but inclusive of working capital adjustments (the “Agena Acquisition”). The Agena Acquisition aligned with our overall acquisition strategy, moved our business towards the life sciences tools sector, and expanded our market opportunities, particularly in Asia. Agena is a leading clinical genomics tools company that develops, manufactures, markets, and supports proprietary instruments and related consumables and services that enable genetic analysis for a broad range of diagnostic and research applications. Using Agena's MassARRAY® instruments and chemical reagent solutions, customers can analyze DNA samples for a variety of high volume clinical testing applications, such as inherited genetic disease testing, pharmacogenetics, various oncology tests, infectious disease testing, and other highly differentiated applications.

We funded the acquisition and transactions relating thereto with cash on hand and borrowings under the Credit Facility (as defined below). Of the cash consideration we paid, approximately $267,000 represented cash consideration to holders of Agena’s preferred and common stock, approximately $2,000 represented cash consideration paid for the settlement of Agena’s warrants, and approximately $31,800 represented cash consideration for the settlement of Agena's vested stock options as of the closing date.

Agena Preliminary Purchase Price Allocation

During the three months ended September 30, 2022, we continued analyses of the valuation of net assets acquired in the Agena Acquisition. This preliminary purchase price allocation is subject to revision as more detailed analyses are completed with respect to prepaid taxes, tax accruals, and deferred tax positions.

The following table summarizes the allocation of the purchase price as of October 20, 2021:

	Life (in years)		Amount
Cash and cash equivalents			$	7,544
Accounts receivable				11,100
Other current assets				25,480
Total current assets				44,124
Property, plant and equipment/noncurrent assets				15,832
Deferred tax asset				811
Intangible assets:
Goodwill		N/A		136,260
Customer relationships		12		103,800
Intellectual property		8		45,400
Tradenames		12		15,700
Total Assets acquired			$	361,927
Accounts payable				2,174
Unearned revenues				2,713
Other current liabilities				12,217
Total current liabilities				17,104
Deferred tax liability				28,223
Other noncurrent liabilities				8,263
Total liabilities assumed			$	53,590
Total purchase price, net of cash acquired			$	300,793

Acquired Goodwill

Acquired goodwill of $136,260, all of which is allocated to the Clinical Genomics reportable segment, represents the value expected to arise from expanded market opportunities, expected synergies, and assembled workforce, none of which qualify as amortizable intangible assets. The goodwill acquired is not deductible for income tax purposes.

Unaudited Pro Forma Information

The following unaudited pro forma financial information presents the combined results of operations of Mesa and Agena as if the acquisition had occurred on April 1, 2021 after giving effect to certain pro forma adjustments. 

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Pro forma total revenues	$	58,749	$	53,521	$	109,202	$	107,074
Pro forma net income		1,504		1,916		329		4,437

The pro forma financial information includes adjustments that are directly attributable to the business combinations and are factually supportable. The pro forma adjustments include incremental amortization of intangible assets, additional stock-based compensation expense for key Agena employees, the removal of interest expense attributable to Agena’s external debt that was paid off as part of the acquisition, and the pro forma tax impact for such adjustments. Cost savings or operating synergies expected to result from the acquisition are not included in the pro forma results. For the three and six months ended September 30, 2022, the pro forma financial information excludes $267 and $623 of non-recurring acquisition-related expenses, respectively. These pro forma results are illustrative only and not indicative of the actual results of operations that would have been achieved nor are they indicative of future results of operations.

XML

Note 3 - Revenue Recognition

6 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

Note 3. Revenue Recognition

We develop, manufacture, market, sell and maintain life sciences tools and quality control instruments and related software, consumables, and services.

Sales of hardware, such as instruments used for molecular and genetic analysis, protein synthesizers, medical meters, wireless sensor systems, and data loggers are generally driven by our acquisition of new customers, growth of existing customers, or customers replacing existing equipment. Hardware sales  may be offered with accompanying perpetual or annual software licenses, which in some cases are required for the hardware to function. We also offer discrete and ongoing service and maintenance contracts on our instruments.

Consumables are typically used on a one-time basis and require frequent replacement in our customers' operating cycles. Consumables such as reagents used for molecular and genetic analysis or solutions used for protein synthesis are critical to the ongoing use of our instruments. Consumables such as biological indicator test strips are used on a standalone basis.

We evaluate our revenues internally based on operating segment, the timing of revenue generation, and the nature of goods and services provided. Typically, discrete revenue is recognized upon shipment of a product or upon completion of a service, while contracted revenue is recognized over a period of time reflective of the performance obligation period in the applicable contract. The significant majority of our revenues and related receivables are generated from contracts with customers that are 12 months or less in duration.

The following tables present disaggregated revenues for the three and six months ended September 30, 2022 and 2021, respectively:

	Three Months Ended September 30, 2022
	Clinical Genomics		Sterilization and Disinfection Control		Biopharmaceutical Development		Calibration Solutions		Total
Discrete Revenues
Consumables	$	11,366	$	14,704	$	4,000	$	865	$	30,935
Hardware and Software		5,527		218		5,988		5,980		17,713
Services		374		543		995		3,587		5,499
Contracted Revenues
Services and Software		1,168		1,499		1,161		774		4,602
Total Revenues	$	18,435	$	16,964	$	12,144	$	11,206	$	58,749

	Three Months Ended September 30, 2021
	Clinical Genomics*		Sterilization and Disinfection Control		Biopharmaceutical Development		Calibration Solutions		Total
Discrete Revenues
Consumables	$	-	$	11,985	$	3,717	$	860	$	16,562
Hardware and Software		-		85		4,942		6,548		11,575
Services		-		493		864		2,981		4,338
Contracted Revenues
Services and Software		-		1,470		1,032		863		3,365
Total Revenues	$	-	$	14,033	$	10,555	$	11,252	$	35,840

	Six Months Ended September 30, 2022
	Clinical Genomics		Sterilization and Disinfection Control		Biopharmaceutical Development		Calibration Solutions		Total
Discrete Revenues
Consumables	$	22,276	$	26,932	$	7,664	$	1,719	$	58,591
Hardware and Software		7,632		524		10,812		11,673		30,641
Services		902		1,308		2,180		6,248		10,638
Contracted Revenues
Services and Software		2,130		2,974		2,455		1,773		9,332
Total Revenues	$	32,940	$	31,738	$	23,111	$	21,413	$	109,202

	Six Months Ended September 30, 2021
	Clinical Genomics*		Sterilization and Disinfection Control		Biopharmaceutical Development		Calibration Solutions		Total
Discrete Revenues
Consumables	$	-	$	24,861	$	7,489	$	1,812	$	34,162
Hardware and Software		-		245		8,335		13,630		22,210
Services		-		1,194		1,446		5,216		7,856
Contracted Revenues
Services and Software		-		2,883		2,162		1,487		6,532
Total Revenues	$	-	$	29,183	$	19,432	$	22,145	$	70,760

*Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021. 

Revenues from external customers are attributed to individual countries based upon the locations to which the products are shipped or exported, or the locations where services are performed, as follows:

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
United States	$	30,989	$	19,384	$	60,111	$	37,839
China		7,480		1,552		11,177		3,717
Other		20,280		14,904		37,914		29,204
Total revenues	$	58,749	$	35,840	$	109,202	$	70,760

Other than China, no foreign country exceeds 10% of total revenues.

Contract Balances

Our contracts have varying payment terms and conditions. Some customers prepay for products and services, resulting in unearned revenues or customer deposits, called contract liabilities. Short-term contract liabilities are included within other accrued expenses and unearned revenues in the accompanying Condensed Consolidated Balance Sheets, and long-term contract liabilities are included within other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets.

A summary of contract liabilities is as follows:

Contract liabilities as of March 31, 2022	$	15,069
Prior year liabilities recognized in revenues during the six months ended September 30, 2022		(3,087	)
Contract liabilities added during the six months ended September 30, 2022, net of revenues recognized		4,284
Contract liabilities balance as of September 30, 2022	$	16,266

Contract liabilities primarily relate to service contracts with original expected service durations of 12 months or less and will be recognized to revenue as time passes.

XML

Note 4 - Fair Value Measurements

6 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Fair Value Disclosures [Text Block]

Note 4. Fair Value Measurements

Our financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, obligations under trade accounts payable, and debt. Due to their short-term nature, the carrying values for cash and cash equivalents, trade accounts receivable, and trade accounts payable approximate fair value. We measure our cash equivalents at fair value using quoted market prices in an active market, and we classify them within Level 1 of the fair value hierarchy. 

Historically, the financial instruments that subject us to the highest concentration of credit risk are cash and cash equivalents and accounts receivable. It is our policy to invest in highly liquid cash equivalent financial instruments with high credit ratings and to maintain low single issuer exposure (except U.S. treasuries). Concentration of credit risk with respect to accounts receivable is limited to customers to which we make significant sales. We reserve an allowance for potential write-offs of accounts receivable using historical collection experience and current and expected future economic and market conditions, but we have not written off any significant accounts to date. To manage credit risk, we consider the creditworthiness of new and existing customers, and we regularly review outstanding balances and payment histories. We  may require pre-payments from customers under certain circumstances and  may limit future purchases until payments are made on past due amounts.

We have outstanding $172,500 aggregate principal of 1.375% convertible senior notes due  August 15, 2025 (the "Notes"). We estimate the fair value of the Notes based on the last actively traded price or observable market input preceding the end of the reporting period and the fair value is approximately correlated to our stock price. The estimated fair value and carrying value of the Notes were as follows:

	September 30, 2022				March 31, 2022
	Carrying Value		Fair Value (Level 2)		Carrying Value		Fair Value (Level 2)
Notes	$	169,816	$	143,930	$	169,365	$	185,438

Assets recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a nonrecurring basis include items such as property and equipment, operating lease assets, goodwill, and other intangible assets. These assets are measured at fair value if determined to be impaired. Fair values assigned to assets acquired and liabilities assumed in the Agena Acquisition, except deferred revenues, were measured using Level 3 inputs. There were no transfers between the levels of the fair value hierarchy during the three and six months ended September 30, 2022 or 2021, respectively.

XML

Note 5 - Supplemental Balance Sheets Information

6 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Supplemental Balance Sheet Disclosures [Text Block]

Note 5. Supplemental Balance Sheets Information

Inventories consist of the following:

	September 30, 2022		March 31, 2022
Raw materials	$	16,433	$	14,172
Work in process		1,833		4,419
Finished goods		9,773		6,015
Total inventories	$	28,039	$	24,606

Prepaid expenses and other consist of the following:

	September 30, 2022		March 31, 2022
Prepaid expenses	$	3,364	$	2,871
Deposits		2,787		1,410
Prepaid income taxes		4,343		2,536
Other current assets		3,541		2,325
Total prepaid expenses and other	$	14,035	$	9,142

Accrued payroll and benefits consist of the following:

	September 30, 2022		March 31, 2022
Bonus payable	$	3,348	$	7,468
Wages and paid-time-off payable		2,081		3,677
Payroll related taxes		1,349		2,069
Other benefits payable		703		1,503
Total accrued payroll and benefits	$	7,481	$	14,717

XML

Note 6 - Goodwill and Intangible Assets, Net

6 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Goodwill and Intangible Assets Disclosure [Text Block]

Note 6. Goodwill and Intangible Assets, Net

Finite-lived intangible assets consist of the following:

	September 30, 2022							March 31, 2022
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Customer relationships	$	228,914	$	(73,566	)	$	155,348	$	244,157	$	(67,469	)	$	176,688
Intellectual property		64,230		(15,762	)		48,468		65,893		(12,620	)		53,273
Other intangibles		24,323		(5,868	)		18,455		25,350		(5,194	)		20,156
Total	$	317,467	$	(95,196	)	$	222,271	$	335,400	$	(85,283	)	$	250,117

Amortization expense for finite-lived intangible assets acquired in a business combination was as follows:

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Amortization in cost of revenues	$	1,691	$	322	$	3,399	$	650
Amortization in general and administrative expense		5,415		3,435		11,027		6,923
Total	$	7,106	$	3,757	$	14,426	$	7,573

For the following fiscal years ending March 31, amortization expense is estimated as follows:

Remainder of 2023	14,030
2024	27,550
2025	25,986
2026	25,247
2027	24,764

The change in the carrying amount of goodwill was as follows:

	Clinical Genomics			Sterilization and Disinfection Control			Biopharmaceutical Development			Calibration Solutions			Total
March 31, 2022	$	135,914		$	29,750		$	88,265		$	37,237		$	291,166
Effect of foreign currency translation		(395	)		(894	)		(12,145	)		(106	)		(13,540	)
Goodwill related to Agena acquisition		380			-			-			-			380
September 30, 2022	$	135,899		$	28,856		$	76,120		$	37,131		$	278,006

XML

Note 7 - Indebtedness

6 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Debt Disclosure [Text Block]

Note 7. Indebtedness

Credit Facility

We maintain a senior credit facility (the “Credit Facility”) that includes 1) a revolving credit facility in an aggregate principal amount of up to $75,000, 2) a swingline loan in an aggregate principal amount not exceeding $5,000, and 3) letters of credit in an aggregate stated amount not exceeding $2,500.  The Credit Facility matures in March 2025. The Credit Facility also provides for an incremental term loan or an increase in revolving commitments in an aggregate principal amount of at a minimum $25,000 and at a maximum $75,000, subject to the satisfaction of certain conditions and lender considerations. As of September 30, 2022, we had $27,000 outstanding under the Credit Facility. 

Amounts borrowed under the Credit Facility bear interest at either a base rate or a Eurodollar rate, plus an applicable spread. The weighted average interest rate on borrowing under our line of credit was 4.9% and 1.5% as of September 30, 2022 and March 31, 2022, respectively. We are obligated to pay quarterly unused commitment fees of between 0.15% and 0.35% of the Credit Facility’s aggregate principal amount, based on our leverage ratio. 

The financial covenants in the Credit Facility include a maximum leverage ratio of 5.0 to 1.0 for the period ended September 30, 2022, except that we  may have a leverage ratio of 5.75 to 1.0 for a period of four consecutive quarters following a permitted acquisition. The Credit Facility also stipulates a minimum fixed charge coverage ratio of 1.25 to 1.0. Other covenants include restrictions on our ability to incur debt, grant liens, make fundamental changes, engage in certain transactions with affiliates, or conduct asset sales. As of  September 30, 2022, we were in compliance with all covenants.

In October 2022, we repaid $2,000 of the outstanding balance on our Credit Facility.

Convertible Notes 

On August 12, 2019, we issued an aggregate principal amount of $172,500 of Notes. The net proceeds from the Notes, after deducting underwriting discounts and commissions and other related offering expenses payable by us, were approximately $167,056. The Notes mature on August 15, 2025, unless earlier repurchased or converted, and bear interest at a rate of 1.375% payable semi-annually in arrears on February 15 and August 15 each year beginning on February 15, 2020. 

Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock, or a combination of cash and shares of our common stock, at our election. Our current intent is to settle conversions entirely in shares of common stock. We will reevaluate this policy from time to time as we receive conversion notices from note holders. The circumstances necessary for conversion were not met during the three months ended September 30, 2022. As of September 30, 2022, the Notes are classified as a long-term liability on our Condensed Consolidated Balance Sheets as the circumstances necessary for conversion were not satisfied as of the end of the period. The if-converted value of the Notes did not exceed the principal balance as of  September 30, 2022.

The net carrying amount of the Notes was as follows:

	September 30, 2022			March 31, 2022
Principal outstanding	$	172,500		$	172,500
Unamortized debt issuance costs		(2,684	)		(3,135	)
Net carrying value	$	169,816		$	169,365

We recognized interest expense on the Notes as follows:

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Coupon interest expense at 1.375%	$	593	$	593	$	1,186	$	1,186
Amortization of debt discounts and issuance costs		227		222		452		443
Total interest and amortization of debt issuance costs	$	820	$	815	$	1,638	$	1,629

The effective interest rate on the notes is approximately 1.9%.

XML

Note 8 - Stockholders' Equity

6 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Share-Based Payment Arrangement [Text Block]

Note 8. Stockholders' Equity

Stock-Based Compensation

During the six months ended September 30, 2022, we issued stock options, restricted stock units ("RSUs") and performance-based restricted stock units ("PSUs") pursuant to the Mesa Laboratories, Inc. 2021 Equity Incentive Plan (the "2021 Equity Plan"), which authorizes the issuance of 330 shares of common stock to eligible participants.

Expense recognized related to stock-based compensation is as follows: 

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Stock-based compensation expense	$	4,371		$	2,039		$	7,803		$	4,236
Amount of income tax (benefit) recognized in earnings		(89	)		(719	)		(2,081	)		(3,504	)
Stock-based compensation expense, net of tax	$	4,282		$	1,320		$	5,722		$	732

Stock-based compensation expense is included in cost of revenues, selling, general and administrative, and research and development expense in the accompanying unaudited Condensed Consolidated Statements of Operations.

The following is a summary of stock option award activity for the six months ended September 30, 2022:

	Stock Options
	Shares Subject to Options			Weighted- Average Exercise Price per Share		Weighted-Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding as of March 31, 2022		202		$	167.14		2.9	$	18,261
Awards granted		42			185.57
Awards forfeited or expired		(6	)		227.42
Awards exercised		(42	)		101.34
Outstanding as of September 30, 2022		196		$	183.13		3.2	$	1,978

The stock options granted during the six months ended September 30, 2022 vest in equal installments on the first, second, and third anniversary of the grant date.

The following is a summary of RSU award activity for the six months ended September 30, 2022:

	Time-Based Restricted Stock Units					Performance-Based Restricted Stock Units
	Number of Shares			Weighted- Average Grant Date Fair Value per Share		Number of Shares			Weighted- Average Grant Date Fair Value per Share
Outstanding as of March 31, 2022(1)		51		$	252.86		55		$	288.45
Awards granted(1)		39			187.44		19			172.15
Performance adjustment(2)		-			-		2			202.00
Awards forfeited		(5	)		241.94		-			-
Awards distributed(2)		(24	)		247.29		(10	)		202.00
Outstanding as of September 30, 2022(1)		61		$	214.47		66		$	265.39

⁽¹⁾ Balances for performance-based restricted stock units ("PSUs") are reflected at target.

⁽²⁾ During the six months ended September 30, 2022, the fiscal year 2020 PSUs vested and were distributed at 126% of target, based on actual performance results and completion of service conditions. 

The outstanding time-based RSUs vest and settle in shares of our common stock on a one-for-one basis. Substantially all of the RSUs granted during the six months ended September 30, 2022 vest in equal installments on the first, second, and third anniversary of the grant date. We recognize the expense relating to RSUs, net of estimated forfeitures, on a straight-line basis over the vesting period.

PSUs vest upon completion of the service period described in the award agreement and based on achievement of the performance targets described in the award agreements. We recognize the expense relating to the performance-based RSUs based on the probable outcome of achievement of the performance targets on a straight-line basis over the service period. 

During the six months ended September 30, 2022, the Compensation Committee of the Board of Directors created a plan to award 19 PSUs at target (the "FY 23 PSUs") that are subject to both service and performance conditions to eligible employees. The performance period for the FY 23 PSUs is from April 1, 2022 until March 31, 2023 and the service period is from April 1, 2022 until March 31, 2025. Of the total FY 23 PSUs granted, 13 vest based on our achievement of specific performance criteria during fiscal year 2023 and they have a grant date fair value of $185.57. The remaining 6 awards will be settled in shares of our common stock, but they are subject to performance criteria that are subjective and as such do not have a grant date. The awards will be marked-to-market each reporting period during the performance period. The quantity of shares that will be issued upon vesting will range from 0% to 200% of the targeted number of shares; if the defined minimum targets are not met, then no shares will vest.

During fiscal year 2020, we awarded 8 PSUs (the "FY 20 PSUs") subject to both service and performance conditions to eligible employees. The FY 20 PSUs had a grant date fair value of $202.00 per share and vested during the six months ended September 30, 2022.  Based on actual performance targets achieved, the awards vested at 126% of target, resulting in a total of 10 awards distributed. 

XML

Note 9 - Earnings Per Share

6 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Earnings Per Share [Text Block]

Note 9. Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings (loss) per share (“diluted EPS”) is computed similarly to basic earnings (loss) per share, except that it includes the potential dilution that could occur if dilutive securities were exercised. Potentially dilutive securities include stock options and both time and performance based RSUs (collectively “stock awards”), as well as common shares underlying the Notes. Stock awards are excluded from the calculation of diluted EPS if they are subject to performance conditions that have not yet been achieved or are antidilutive. Diluted EPS considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would then have an antidilutive effect. There was no dilution in our diluted EPS calculation for the six months ended September 30, 2022 as we incurred a net loss and the effect would have been antidilutive.

The impact of the assumed conversion of the Notes calculated under the if-converted method was antidilutive, and as such, shares underlying the Notes were excluded from the diluted EPS calculation for the three and six months ended September 30, 2022 and September 30, 2021. 

The following table presents a reconciliation of the denominators used in the computation of basic and diluted earnings (loss) per share:

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022			2021
Net income (loss) available for shareholders	$	1,306	$	3,720	$	(132	)	$	5,715
Weighted average outstanding shares of common stock		5,323		5,211		5,298			5,182
Dilutive effect of stock options		27		109		-			109
Dilutive effect of RSUs		14		24		-			33
Fully diluted shares		5,364		5,344		5,298			5,324
Basic earnings (loss) per share	$	0.25	$	0.71	$	(0.02	)	$	1.10
Diluted earnings (loss) per share	$	0.24	$	0.70	$	(0.02	)	$	1.07

The following stock awards were excluded from the calculation of diluted EPS:

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Assumed conversion of the Notes		608		608		608		608
Stock awards that were anti-dilutive		154		43		328		40
Stock awards subject to performance conditions		60		8		52		8
Total stock awards excluded from diluted EPS		822		659		988		656

XML

Note 10 - Income Taxes

6 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Income Tax Disclosure [Text Block]

Note 10. Income Taxes

For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year-to-date pre-tax income. Each quarter, our estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. Additionally, the tax effects of significant unusual or infrequently occurring items are recognized as discrete items in the interim period in which the events occur. There is a potential for volatility in the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, settlement with taxing authorities, and foreign currency fluctuations.

Our effective income tax rate was (93.5%) for the six months ended September 30, 2022, and 4.1% for the six months ended September 30, 2021. The effective tax rate for the six months ended September 30, 2022 differed from the statutory federal rate of 21% primarily due to the share-based payment awards for employees and the effect of income generated in foreign jurisdictions.  The effective tax rate for the first six months of 2023 was lower than the same period in 2022 primarily due to the share based compensation and the effect of income in foreign jurisdictions.

XML

Note 11 - Commitments and Contingencies

6 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

Note 11. Commitments and Contingencies

We review the adequacy of our legal reserves on a quarterly basis and establish reserves for loss contingencies that are both probable and reasonably estimable. As of September 30, 2022, there were no material legal reserves recorded on the accompanying unaudited Condensed Consolidated Balance Sheets. 

XML

Note 12 - Segment Information

6 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 12. Segment Information

During fiscal year 2022, we realigned our financial reporting segments to reflect how management evaluates the business and allocates resources. The acquisition of Agena expanded our presence further into the life sciences tools market and provided an impetus for the creation of our new Clinical Genomics reportable segment. The strategic shift in our business also resulted in a change to the way we manage other business units, and as a result, our historical Instruments and Continuous Monitoring reportable segments have been combined to create Calibration Solutions. Prior year amounts presented have been reclassified to conform to current year presentation. Our change in financial reporting segments has not resulted in any change to previously reported consolidated amounts.

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Revenues:
Clinical Genomics	$	18,435		$	-		$	32,940		$	-
Sterilization and Disinfection Control		16,964			14,033			31,738			29,183
Biopharmaceutical Development		12,144			10,555			23,111			19,432
Calibration Solutions		11,206			11,252			21,413			22,145
Total revenues (a)	$	58,749		$	35,840		$	109,202		$	70,760
Gross profit
Clinical Genomics	$	10,641		$	-		$	18,490		$	-
Sterilization and Disinfection Control		12,199			10,486			22,967			21,914
Biopharmaceutical Development		7,557			6,601			14,634			11,293
Calibration Solutions		6,007			6,128			11,671			12,240
Reportable segment gross profit		36,404			23,215			67,762			45,447
Corporate and Other (b)		(18	)		(75	)		(35	)		(96	)
Gross profit	$	36,386		$	23,140		$	67,727		$	45,351
Reconciling Items:
Operating expenses		32,391			18,939			68,326			38,027
Operating income (loss)		3,995			4,201			(599	)		7,324
Nonoperating expense (income), net		611			(342	)		1,429			1,363
Earnings (loss) before income taxes	$	3,384		$	4,543		$	(2,028	)	$	5,961

^(a) Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

^(b) Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other. 

The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.

	September 30,		March 31,
	2022		2022
Clinical Genomics	$	12,600	$	11,802
Sterilization and Disinfection Control		2,864		2,176
Biopharmaceutical Development		5,214		4,495
Calibration Solutions		7,361		6,133
Total inventories	$	28,039	$	24,606

XML

Significant Accounting Policies (Policies)

6 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Description of Business [Policy Text Block]

Description of Business

In this quarterly report on Form 10-Q, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries is collectively referred to as “we,” “us,” “our,” the “Company” or “Mesa.”

We are a multinational manufacturer, developer, and seller of life science tools and critical quality control products and services, many of which are sold into niche markets that are driven by regulatory requirements. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe, and Asia Pacific, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins.

As of September 30, 2022, we managed our operations in four reportable segments, or divisions:

● Clinical Genomics - develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics and oncology related applications.

● Sterilization and Disinfection Control - manufactures and sells biological, cleaning, and chemical indicators which are used to assess the effectiveness of sterilization and disinfection processes in the hospital, medical device, and pharmaceutical industries. The division also provides testing and laboratory services, mainly to the dental industry. 

● Biopharmaceutical Development - develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufacture of biotherapeutic drugs. 

● Calibration Solutions - develops, manufactures, and sells quality control and calibration products used to measure or calibrate temperature, pressure, pH, humidity, and other chemical or physical parameters for health and safety purposes, primarily in hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. 

Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for the fair statement of our financial position and results of operations. The results of operations for the interim periods are not necessarily indicative of results that may be achieved for the entire year. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. We made no material changes to the application of our significant accounting policies that were disclosed in our Form 10-K. This quarterly report should be read in conjunction with the consolidated financial statements included in our annual report on Form 10-K for the year ended  March 31, 2022.

Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year, references to the first quarter of fiscal year 2023 refer to the period from April 1, 2022 through June 30, 2022, and references to the second quarter of fiscal year 2023 refer to the period from July 1, 2022 through September 30, 2022. References to “fiscal year 2022” refer to the fiscal year ended March 31, 2022, and to “fiscal year 2023” refer to the fiscal year ending March 31, 2023.

Reclassification, Comparability Adjustment [Policy Text Block]

Prior Period Reclassification

Certain amounts presented for prior periods related to the Biopharmaceutical Development division in Note 3. "Revenue Recognition" have been reclassified out of revenues from consumables and into revenues from hardware and services. These reclassifications have not resulted in any change to the Condensed Consolidated Financial Statements for and periods presented in this Form 10-Q.

Risk and Uncertainties, Policy [Policy Text Block]

Risks and Uncertainties

The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgement about the outcome of future events. The business and economic uncertainty resulting from the novel coronavirus pandemic ("COVID-19"), supply chain challenges, cost pressure and the overall effects of the current high inflation environment on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Issued Accounting Pronouncements

We have reviewed all recently issued accounting pronouncements and have concluded that they are either not applicable to us or are not expected to have a significant impact on our consolidated financial statements.

XML

Note 2 - Significant Transactions (Tables)

6 Months Ended

Sep. 30, 2022

Notes Tables

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

	Life (in years)		Amount
Cash and cash equivalents			$	7,544
Accounts receivable				11,100
Other current assets				25,480
Total current assets				44,124
Property, plant and equipment/noncurrent assets				15,832
Deferred tax asset				811
Intangible assets:
Goodwill		N/A		136,260
Customer relationships		12		103,800
Intellectual property		8		45,400
Tradenames		12		15,700
Total Assets acquired			$	361,927
Accounts payable				2,174
Unearned revenues				2,713
Other current liabilities				12,217
Total current liabilities				17,104
Deferred tax liability				28,223
Other noncurrent liabilities				8,263
Total liabilities assumed			$	53,590
Total purchase price, net of cash acquired			$	300,793

Business Acquisition, Pro Forma Information [Table Text Block]

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Pro forma total revenues	$	58,749	$	53,521	$	109,202	$	107,074
Pro forma net income		1,504		1,916		329		4,437

XML

Note 3 - Revenue Recognition (Tables)

6 Months Ended

Sep. 30, 2022

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three Months Ended September 30, 2022
	Clinical Genomics		Sterilization and Disinfection Control		Biopharmaceutical Development		Calibration Solutions		Total
Discrete Revenues
Consumables	$	11,366	$	14,704	$	4,000	$	865	$	30,935
Hardware and Software		5,527		218		5,988		5,980		17,713
Services		374		543		995		3,587		5,499
Contracted Revenues
Services and Software		1,168		1,499		1,161		774		4,602
Total Revenues	$	18,435	$	16,964	$	12,144	$	11,206	$	58,749

	Three Months Ended September 30, 2021
	Clinical Genomics*		Sterilization and Disinfection Control		Biopharmaceutical Development		Calibration Solutions		Total
Discrete Revenues
Consumables	$	-	$	11,985	$	3,717	$	860	$	16,562
Hardware and Software		-		85		4,942		6,548		11,575
Services		-		493		864		2,981		4,338
Contracted Revenues
Services and Software		-		1,470		1,032		863		3,365
Total Revenues	$	-	$	14,033	$	10,555	$	11,252	$	35,840

	Six Months Ended September 30, 2022
	Clinical Genomics		Sterilization and Disinfection Control		Biopharmaceutical Development		Calibration Solutions		Total
Discrete Revenues
Consumables	$	22,276	$	26,932	$	7,664	$	1,719	$	58,591
Hardware and Software		7,632		524		10,812		11,673		30,641
Services		902		1,308		2,180		6,248		10,638
Contracted Revenues
Services and Software		2,130		2,974		2,455		1,773		9,332
Total Revenues	$	32,940	$	31,738	$	23,111	$	21,413	$	109,202

	Six Months Ended September 30, 2021
	Clinical Genomics*		Sterilization and Disinfection Control		Biopharmaceutical Development		Calibration Solutions		Total
Discrete Revenues
Consumables	$	-	$	24,861	$	7,489	$	1,812	$	34,162
Hardware and Software		-		245		8,335		13,630		22,210
Services		-		1,194		1,446		5,216		7,856
Contracted Revenues
Services and Software		-		2,883		2,162		1,487		6,532
Total Revenues	$	-	$	29,183	$	19,432	$	22,145	$	70,760

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
United States	$	30,989	$	19,384	$	60,111	$	37,839
China		7,480		1,552		11,177		3,717
Other		20,280		14,904		37,914		29,204
Total revenues	$	58,749	$	35,840	$	109,202	$	70,760

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

Contract liabilities as of March 31, 2022	$	15,069
Prior year liabilities recognized in revenues during the six months ended September 30, 2022		(3,087	)
Contract liabilities added during the six months ended September 30, 2022, net of revenues recognized		4,284
Contract liabilities balance as of September 30, 2022	$	16,266

XML

Note 4 - Fair Value Measurements (Tables)

6 Months Ended

Sep. 30, 2022

Notes Tables

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

	September 30, 2022				March 31, 2022
	Carrying Value		Fair Value (Level 2)		Carrying Value		Fair Value (Level 2)
Notes	$	169,816	$	143,930	$	169,365	$	185,438

XML

Note 5 - Supplemental Balance Sheets Information (Tables)

6 Months Ended

Sep. 30, 2022

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	September 30, 2022		March 31, 2022
Raw materials	$	16,433	$	14,172
Work in process		1,833		4,419
Finished goods		9,773		6,015
Total inventories	$	28,039	$	24,606

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

	September 30, 2022		March 31, 2022
Prepaid expenses	$	3,364	$	2,871
Deposits		2,787		1,410
Prepaid income taxes		4,343		2,536
Other current assets		3,541		2,325
Total prepaid expenses and other	$	14,035	$	9,142

Schedule of Accrued Liabilities [Table Text Block]

	September 30, 2022		March 31, 2022
Bonus payable	$	3,348	$	7,468
Wages and paid-time-off payable		2,081		3,677
Payroll related taxes		1,349		2,069
Other benefits payable		703		1,503
Total accrued payroll and benefits	$	7,481	$	14,717

XML

Note 6 - Goodwill and Intangible Assets, Net (Tables)

6 Months Ended

Sep. 30, 2022

Notes Tables

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	September 30, 2022							March 31, 2022
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Customer relationships	$	228,914	$	(73,566	)	$	155,348	$	244,157	$	(67,469	)	$	176,688
Intellectual property		64,230		(15,762	)		48,468		65,893		(12,620	)		53,273
Other intangibles		24,323		(5,868	)		18,455		25,350		(5,194	)		20,156
Total	$	317,467	$	(95,196	)	$	222,271	$	335,400	$	(85,283	)	$	250,117

Finite-Lived Intangible Assets Amortization Expense [Table Text Block]

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Amortization in cost of revenues	$	1,691	$	322	$	3,399	$	650
Amortization in general and administrative expense		5,415		3,435		11,027		6,923
Total	$	7,106	$	3,757	$	14,426	$	7,573

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Remainder of 2023	14,030
2024	27,550
2025	25,986
2026	25,247
2027	24,764

Schedule of Goodwill [Table Text Block]

	Clinical Genomics			Sterilization and Disinfection Control			Biopharmaceutical Development			Calibration Solutions			Total
March 31, 2022	$	135,914		$	29,750		$	88,265		$	37,237		$	291,166
Effect of foreign currency translation		(395	)		(894	)		(12,145	)		(106	)		(13,540	)
Goodwill related to Agena acquisition		380			-			-			-			380
September 30, 2022	$	135,899		$	28,856		$	76,120		$	37,131		$	278,006

XML

Note 7 - Indebtedness (Tables)

6 Months Ended

Sep. 30, 2022

Notes Tables

Convertible Debt [Table Text Block]

	September 30, 2022			March 31, 2022
Principal outstanding	$	172,500		$	172,500
Unamortized debt issuance costs		(2,684	)		(3,135	)
Net carrying value	$	169,816		$	169,365

Interest Expense on Convertible Debt [Table Text Block]

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Coupon interest expense at 1.375%	$	593	$	593	$	1,186	$	1,186
Amortization of debt discounts and issuance costs		227		222		452		443
Total interest and amortization of debt issuance costs	$	820	$	815	$	1,638	$	1,629

XML

Note 8 - Stockholders' Equity (Tables)

6 Months Ended

Sep. 30, 2022

Notes Tables

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Stock-based compensation expense	$	4,371		$	2,039		$	7,803		$	4,236
Amount of income tax (benefit) recognized in earnings		(89	)		(719	)		(2,081	)		(3,504	)
Stock-based compensation expense, net of tax	$	4,282		$	1,320		$	5,722		$	732

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Stock Options
	Shares Subject to Options			Weighted- Average Exercise Price per Share		Weighted-Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
Outstanding as of March 31, 2022		202		$	167.14		2.9	$	18,261
Awards granted		42			185.57
Awards forfeited or expired		(6	)		227.42
Awards exercised		(42	)		101.34
Outstanding as of September 30, 2022		196		$	183.13		3.2	$	1,978

Share-Based Payment Arrangement, Activity [Table Text Block]

	Time-Based Restricted Stock Units					Performance-Based Restricted Stock Units
	Number of Shares			Weighted- Average Grant Date Fair Value per Share		Number of Shares			Weighted- Average Grant Date Fair Value per Share
Outstanding as of March 31, 2022(1)		51		$	252.86		55		$	288.45
Awards granted(1)		39			187.44		19			172.15
Performance adjustment(2)		-			-		2			202.00
Awards forfeited		(5	)		241.94		-			-
Awards distributed(2)		(24	)		247.29		(10	)		202.00
Outstanding as of September 30, 2022(1)		61		$	214.47		66		$	265.39

XML

Note 9 - Earnings Per Share (Tables)

6 Months Ended

Sep. 30, 2022

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022			2021
Net income (loss) available for shareholders	$	1,306	$	3,720	$	(132	)	$	5,715
Weighted average outstanding shares of common stock		5,323		5,211		5,298			5,182
Dilutive effect of stock options		27		109		-			109
Dilutive effect of RSUs		14		24		-			33
Fully diluted shares		5,364		5,344		5,298			5,324
Basic earnings (loss) per share	$	0.25	$	0.71	$	(0.02	)	$	1.10
Diluted earnings (loss) per share	$	0.24	$	0.70	$	(0.02	)	$	1.07

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended September 30,				Six Months Ended September 30,
	2022		2021		2022		2021
Assumed conversion of the Notes		608		608		608		608
Stock awards that were anti-dilutive		154		43		328		40
Stock awards subject to performance conditions		60		8		52		8
Total stock awards excluded from diluted EPS		822		659		988		656

XML

Note 12 - Segment Information (Tables)

6 Months Ended

Sep. 30, 2022

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended September 30,						Six Months Ended September 30,
	2022			2021			2022			2021
Revenues:
Clinical Genomics	$	18,435		$	-		$	32,940		$	-
Sterilization and Disinfection Control		16,964			14,033			31,738			29,183
Biopharmaceutical Development		12,144			10,555			23,111			19,432
Calibration Solutions		11,206			11,252			21,413			22,145
Total revenues (a)	$	58,749		$	35,840		$	109,202		$	70,760
Gross profit
Clinical Genomics	$	10,641		$	-		$	18,490		$	-
Sterilization and Disinfection Control		12,199			10,486			22,967			21,914
Biopharmaceutical Development		7,557			6,601			14,634			11,293
Calibration Solutions		6,007			6,128			11,671			12,240
Reportable segment gross profit		36,404			23,215			67,762			45,447
Corporate and Other (b)		(18	)		(75	)		(35	)		(96	)
Gross profit	$	36,386		$	23,140		$	67,727		$	45,351
Reconciling Items:
Operating expenses		32,391			18,939			68,326			38,027
Operating income (loss)		3,995			4,201			(599	)		7,324
Nonoperating expense (income), net		611			(342	)		1,429			1,363
Earnings (loss) before income taxes	$	3,384		$	4,543		$	(2,028	)	$	5,961

	September 30,		March 31,
	2022		2022
Clinical Genomics	$	12,600	$	11,802
Sterilization and Disinfection Control		2,864		2,176
Biopharmaceutical Development		5,214		4,495
Calibration Solutions		7,361		6,133
Total inventories	$	28,039	$	24,606

XML

Note 2 - Significant Transactions (Details Textual) - USD ($) $ in Thousands			3 Months Ended	6 Months Ended
	Oct. 20, 2021		Sep. 30, 2022	Sep. 30, 2022	Mar. 31, 2022
Goodwill, Ending Balance			$ 278,006	$ 278,006	$ 291,166
Agena [Member]
Payments to Acquire Businesses, Gross	$ 300,793
Payments to Acquire Businesses, Settlement of Options	31,800
Goodwill, Ending Balance	136,260	[1]			$ 136,260
Agena [Member] | Acquisition-related Costs [Member]
Business Combination, Acquisition Related Costs			$ 267	$ 623
Agena [Member] | Agena Warrants [Member]
Payments to Acquire Businesses, Gross	2,000
Agena [Member] | Holders of Agena Preferred and Common Stock [Member]
Payments to Acquire Businesses, Gross	$ 267,000

[1] Acquired goodwill of $140,022, all of which is allocated to the Clinical Genomics reportable segment, represents the value expected to arise from the value of expanded market opportunities, expected synergies, and assembled workforce, none of which qualify as amortizable intangible assets. The goodwill acquired is not deductible for income tax purposes.

XML

Note 2 - Significant Transactions - Allocation of Preliminary Price (Details) - USD ($) $ in Thousands		Oct. 20, 2021		Sep. 30, 2022	Mar. 31, 2022
Goodwill, Ending Balance				$ 278,006	$ 291,166
Agena [Member]
Cash and cash equivalents		$ 7,544
Accounts receivable	[1]	11,100
Other current assets	[2]	25,480
Total current assets		44,124
Property, plant and equipment/noncurrent assets		15,832
Deferred tax asset		811
Goodwill, Ending Balance		136,260	[3]		$ 136,260
Total Assets acquired		361,927
Accounts payable		2,174
Unearned revenues		2,713
Other current liabilities		12,217
Total current liabilities		17,104
Deferred tax liability		28,223
Other noncurrent liabilities		8,263
Total liabilities assumed		53,590
Total purchase price, net of cash acquired		$ 300,793
Agena [Member] | Customer Relationships [Member]
Intangible assets, life (Year)		12 years
Intangible assets	[4]	$ 103,800
Intangible assets, life (Year)		12 years
Agena [Member] | Intellectual Property [Member]
Intangible assets, life (Year)		8 years
Intangible assets	[4]	$ 45,400
Intangible assets, life (Year)		8 years
Agena [Member] | Trade Names [Member]
Intangible assets, life (Year)		12 years
Intangible assets	[4]	$ 15,700
Intangible assets, life (Year)		12 years

[1] Trade receivables, net, which is expected to be collected.

[2] Includes $7,462 of inventory step-up, which was amortized entirely within fiscal year 2022. Our evaluation of the valuation of inventory was complete as of March 31, 2022.

[3] Acquired goodwill of $140,022, all of which is allocated to the Clinical Genomics reportable segment, represents the value expected to arise from the value of expanded market opportunities, expected synergies, and assembled workforce, none of which qualify as amortizable intangible assets. The goodwill acquired is not deductible for income tax purposes.

[4] Customer relationships, intellectual property, and tradenames are currently expected to be amortized on a straight line basis over a weighted average 8.3 year period. The identified intangible assets will be amortized on a straight line basis over their useful lives, which approximates the pattern over which the assets' economic benefits are expected to be consumed over time. Amortization expense for customer relationships and tradenames will be amortized to general and administrative expenses; amortization expense for intellectual property will be recorded to cost of revenues. During the period from October 20, 2021 until March 31, 2022, $6,728 of amortization expense was recorded to general and administrative costs and $2,538 of amortization expense was recorded to cost of revenues in the Clinical Genomics Division, including the cumulative effect catch up. Our valuation of intangible assets is considered to be complete as of March 31, 2022. Going forward, we expect to record amortization expense of $3,668 and $1,419 to general and administrative costs and costs of revenues, respectively, each quarter.

XML

Note 2 - Significant Transactions - Unaudited Pro Forma Information (Details) - Agena [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Pro forma total revenues	$ 58,749	$ 53,521	$ 109,202	$ 107,074
Pro forma net income	$ 1,504	$ 1,916	$ 329	$ 4,437

XML

Note 3 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues		$ 58,749	$ 35,840	$ 109,202	$ 70,760
Consumables [Member] | Transferred at Point in Time [Member]
Revenues		30,935	16,562	58,591	34,162
Hardware and Software [Member] | Transferred at Point in Time [Member]
Revenues		17,713	11,575	30,641	22,210
Service [Member] | Transferred at Point in Time [Member]
Revenues		5,499	4,338	10,638	7,856
Services and Software [Member] | Transferred over Time [Member]
Revenues		4,602	3,365	9,332	6,532
Operating Segments [Member]
Revenues	[1]	58,749	35,840	109,202	70,760
Operating Segments [Member] | Clinical Genomics [Member]
Revenues		18,435	0	32,940	0
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Revenues		16,964	14,033	31,738	29,183
Operating Segments [Member] | Biopharmaceutical Development [Member]
Revenues		12,144	10,555	23,111	19,432
Operating Segments [Member] | Calibration Solutions [Member]
Revenues	[2]	11,206	11,252	21,413	22,145
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]
Revenues		11,366	0	22,276	0
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]
Revenues		14,704	11,985	26,932	24,861
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]
Revenues		4,000	3,717	7,664	7,489
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]
Revenues		865	860	1,719	1,812
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]
Revenues		5,527	0	7,632	0
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]
Revenues		218	85	524	245
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]
Revenues		5,988	4,942	10,812	8,335
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]
Revenues	[2]	5,980	6,548	11,673	13,630
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]
Revenues		374	0	902	0
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]
Revenues		543	493	1,308	1,194
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]
Revenues		995	864	2,180	1,446
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]
Revenues	[2]	3,587	2,981	6,248	5,216
Operating Segments [Member] | Services and Software [Member] | Transferred over Time [Member] | Clinical Genomics [Member]
Revenues		1,168	0	2,130	0
Operating Segments [Member] | Services and Software [Member] | Transferred over Time [Member] | Sterilization and Disinfection Control [Member]
Revenues		1,499	1,470	2,974	2,883
Operating Segments [Member] | Services and Software [Member] | Transferred over Time [Member] | Biopharmaceutical Development [Member]
Revenues		1,161	1,032	2,455	2,162
Operating Segments [Member] | Services and Software [Member] | Transferred over Time [Member] | Calibration Solutions [Member]
Revenues		$ 774	$ 863	$ 1,773	$ 1,487

[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals

[2] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.

XML

Note 3 - Revenue Recognition - Revenues From External Customers (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues	$ 58,749	$ 35,840	$ 109,202	$ 70,760
UNITED STATES
Revenues	30,989	19,384	60,111	37,839
CHINA
Revenues	7,480	1,552	11,177	3,717
Other [Member]
Revenues	$ 20,280	$ 14,904	$ 37,914	$ 29,204

XML

Note 3 - Revenue Recognition - Contract Liabilities (Details) $ in Thousands	6 Months Ended
	Sep. 30, 2022 USD ($)
Contract liabilities, balance	$ 15,069
Prior year liabilities recognized in revenues during the six months ended September 30, 2022	(3,087)
Contract liabilities added during the six months ended September 30, 2022, net of revenues recognized	4,284
Contract liabilities, balance	$ 16,266

XML

Note 4 - Fair Value Measurements (Details Textual) - Senior Notes [Member] - The Notes [Member] - USD ($) $ in Millions	Sep. 30, 2022	Mar. 31, 2022	Aug. 12, 2019
Long-term Debt, Gross	$ 172.5	$ 172.5
Debt Instrument, Interest Rate, Stated Percentage		1.375%	1.375%

XML

Note 4 - Fair Value Measurements - Fair Value and Carrying Value of the Notes (Details) - Senior Notes [Member] - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2021
Reported Value Measurement [Member]
Notes	$ 169,816	$ 169,365
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Notes	$ 143,930	$ 185,438

XML

Note 5 - Supplemental Balance Sheets Information - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Raw materials	$ 16,433	$ 14,172
Work in process	1,833	4,419
Finished goods	9,773	6,015
Total inventories	$ 28,039	$ 24,606

XML

Note 5 - Supplemental Balance Sheets Information - Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Prepaid expenses	$ 3,364	$ 2,871
Deposits	2,787	1,410
Prepaid income taxes	4,343	2,536
Other current assets	3,541	2,325
Total prepaid expenses and other	$ 14,035	$ 9,142

XML

Note 5 - Supplemental Balance Sheets Information - Accrued Payroll and Benefits (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Wages and paid-time-off payable	$ 2,081	$ 3,677
Payroll related taxes	1,349	2,069
Other benefits payable	703	1,503
Total accrued payroll and benefits	7,481	14,717
Other Accrued Expenses [Member]
Bonus payable	$ 3,348	$ 7,468

XML

Note 6 - Goodwill and Intangible Assets, Net - Other Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Gross carrying amount	$ 317,467	$ 335,400
Accumulated amortization	(95,196)	(85,283)
Net carrying amount	222,271	250,117
Customer Relationships [Member]
Gross carrying amount	228,914	244,157
Accumulated amortization	(73,566)	(67,469)
Net carrying amount	155,348	176,688
Intellectual Property [Member]
Gross carrying amount	64,230	65,893
Accumulated amortization	(15,762)	(12,620)
Net carrying amount	48,468	53,273
Other Intangible Assets [Member]
Gross carrying amount	24,323	25,350
Accumulated amortization	(5,868)	(5,194)
Net carrying amount	$ 18,455	$ 20,156

XML

Note 6 - Goodwill and Intangible Assets, Net - Amortization Expense for Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Amortization of Intangible Assets	$ 7,106	$ 3,757	$ 14,426	$ 7,573
Cost of Sales [Member]
Amortization of Intangible Assets	1,691	322	3,399	650
General and Administrative Expense [Member]
Amortization of Intangible Assets	$ 5,415	$ 3,435	$ 11,027	$ 6,923

XML

Note 6 - Goodwill and Intangible Assets, Net - Estimated Amortization Expense (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Remainder of 2023	$ 14,030
2024	27,550
2025	25,986
2026	25,247
2027	$ 24,764

XML

Note 6 - Goodwill and Intangible Assets, Net - Change in the Carrying Amount of Goodwill (Details) $ in Thousands	6 Months Ended
	Sep. 30, 2022 USD ($)
Goodwill	$ 291,166
Effect of foreign currency translation	(13,540)
Goodwill related to Agena acquisition	380
Goodwill	278,006
Clinical Genomics [Member] | Operating Segments [Member]
Goodwill	135,914
Effect of foreign currency translation	(395)
Goodwill related to Agena acquisition	380
Goodwill	135,899
Sterilization and Disinfection Control [Member] | Operating Segments [Member]
Goodwill	29,750
Effect of foreign currency translation	(894)
Goodwill related to Agena acquisition	0
Goodwill	28,856
Biopharmaceutical Development [Member] | Operating Segments [Member]
Goodwill	88,265
Effect of foreign currency translation	(12,145)
Goodwill related to Agena acquisition	0
Goodwill	76,120
Calibration Solutions [Member] | Operating Segments [Member]
Goodwill	37,237
Effect of foreign currency translation	(106)
Goodwill related to Agena acquisition	0
Goodwill	$ 37,131

XML

Note 7 - Indebtedness (Details Textual) - USD ($) $ in Thousands	Mar. 05, 2021	Aug. 12, 2019	Sep. 30, 2022	Mar. 31, 2022	Mar. 31, 2021
Long-Term Line of Credit, Total			$ 27,000	$ 49,000
Senior Secured Credit Agreement [Member]
Long-Term Line of Credit, Total			$ 27,000
Debt Instrument, Covenant, Maximum Total Leverage Ratio for the First Four Testing Dates	10
Debt Instrument, Covenant, Maximum Total Leverage Ratio for the Sixth, Seventh, and Eighth Testing Dates	5.0
Debt Instrument, Covenant, Maximum Conditional Total Leverage Ratio Following an Acquisition	5.75
Senior Secured Credit Agreement [Member] | Minimum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.15%
Fixed Charge Coverage Ratio	1.25
Senior Secured Credit Agreement [Member] | Minimum [Member] | The Credit Facility Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000
Senior Secured Credit Agreement [Member] | Maximum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.35%
Senior Secured Credit Agreement [Member] | Maximum [Member] | The Credit Facility Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 75,000
Senior Secured Credit Agreement [Member] | Swingline Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity	5,000
Senior Secured Credit Agreement [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	75,000
Senior Secured Credit Agreement [Member] | Letter of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 2,500
The Notes [Member] | Senior Notes [Member]
Debt Instrument, Face Amount		$ 172,500
Proceeds from Convertible Debt		$ 167,056
Debt Instrument, Interest Rate, Stated Percentage		1.375%		1.375%
Debt Instrument, Interest Rate, Effective Percentage					1.90%

XML

Note 7 - Indebtedness - Carrying Amount of the Notes (Details) - The Notes [Member] - Senior Notes [Member] - USD ($) $ in Thousands	Sep. 30, 2022	Mar. 31, 2022
Principal outstanding	$ 172,500	$ 172,500
Unamortized debt issuance costs	(2,684)	(3,135)
Net carrying value	$ 169,816	$ 169,365

XML

Note 7 - Indebtedness - Interest Expense on the Notes (Details) - The Notes [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Coupon interest expense at 1.375%	$ 593	$ 593	$ 1,186	$ 1,186
Amortization of debt discounts and issuance costs	227	222	452	443
Total interest and amortization of debt issuance costs	$ 820	$ 815	$ 1,638	$ 1,629

XML

Note 8 - Stockholders' Equity (Details Textual) - $ / shares shares in Thousands	6 Months Ended	12 Months Ended
	Sep. 30, 2022	Mar. 31, 2020	Mar. 31, 2022
The FY23 PSUs Member | Eligible Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	19
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)	13
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)	$ 185.57
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	6
The FY23 PSUs Member | Eligible Employees [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage	0.00%
The FY23 PSUs Member | Eligible Employees [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage	200.00%
The FY20 PSUs [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	10
Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage		126.00%
Share-based Compensation Arrangement by Share-based Payment Award, Vested, Percentage of Finance Performance Target	126.00%
The FY20 PSUs [Member] | Eligible Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 202.00
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		10
The 2021 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)			330

XML

Note 8 - Stockholders' Equity - Allocation of Share-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock-based compensation expense	$ 4,371	$ 2,039	$ 7,803	$ 4,236
Amount of income tax (benefit) recognized in earnings	(89)	(719)	(2,081)	(3,504)
Stock-based compensation expense, net of tax	$ 4,282	$ 1,320	$ 5,722	$ 732

XML

Note 8 - Stockholders' Equity - Stock Option and Non-vested Stock Award Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022
Options outstanding (in shares)	202
Options outstanding, weighted average exercise price (in dollars per share)	$ 167.14
Outstanding, Weighted- Average Remaining Contractual Life (Year)	3 years 2 months 12 days	2 years 10 months 24 days
Outstanding, Aggregate Intrinsic Value	$ 18,261
Options granted (in shares)	42
Awards granted, weighted average exercise price (in dollars per share)	$ 185,570
Options forfeited or expired (in shares)	(6)
Awards forfeited or expired, weighted average exercise price (in dollars per share)	$ 227,420
Awards exercised (in shares)	(42)
Awards exercised (in dollars per share)	$ 101,340
Options outstanding (in shares)	196	202
Outstanding as of September 30, 2022 (in dollars per share)	$ 183.13	$ 167.14
Outstanding, Aggregate Intrinsic Value	$ 1,978	$ 18,261

XML

Note 8 - Stockholders' Equity - Restricted Stock Unit Activity (Details)	6 Months Ended
	Sep. 30, 2022 $ / shares shares
Restricted Stock Units (RSUs) [Member]
Outstanding as of March 31, 2022(1) (in shares) | shares	51	[1]
Outstanding as of March 31, 2022(1) (in dollars per share) | $ / shares	$ 252.86	[1]
Awards granted(1) (in shares) | shares	39	[1]
Awards granted(1) (in dollars per share) | $ / shares	$ 187.44	[1]
Performance adjustment(2) (in shares) | shares	0	[2]
Performance adjustment(2) (in dollars per share) | $ / shares	$ 0	[2]
Awards forfeited (in shares) | shares	(5)
Awards forfeited (in dollars per share) | $ / shares	$ 241.94
Awards distributed(2) (in shares) | shares	(24)
Awards distributed, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 247.29
Outstanding as of September 30, 2022(1) (in shares) | shares	61	[1],[2]
Outstanding as of September 30, 2022(1) (in dollars per share) | $ / shares	$ 214.47	[1]
Performance Stock Units [Member]
Outstanding as of March 31, 2022(1) (in shares) | shares	55	[1]
Outstanding as of March 31, 2022(1) (in dollars per share) | $ / shares	$ 288.45	[1]
Awards granted(1) (in shares) | shares	19	[1]
Awards granted(1) (in dollars per share) | $ / shares	$ 172.15	[1]
Performance adjustment(2) (in shares) | shares	2	[2]
Performance adjustment(2) (in dollars per share) | $ / shares	$ 202.00	[2]
Awards forfeited (in shares) | shares	0
Awards forfeited (in dollars per share) | $ / shares	$ 0
Awards distributed(2) (in shares) | shares	(10)
Awards distributed, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 202.00
Outstanding as of September 30, 2022(1) (in shares) | shares	66	[1],[2]
Outstanding as of September 30, 2022(1) (in dollars per share) | $ / shares	$ 265.39	[1]

[1] Balances for performance-based restricted stock units ("PSUs") are reflected at target.

[2] During the three months ended June 30, 2022, the fiscal year 2020 PSUs vested and were paid at 126% of target, based on actual performance results and completion of service conditions.

XML

Note 9 - Earnings Per Share - Computation of Net Income Per Share, Basic & Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended			6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Net (loss) income	$ 1,306	$ 3,720	$ 1,995	$ (132)	$ 5,715
Weighted average outstanding shares of common stock (in shares)	5,323	5,211		5,298	5,182
Fully diluted shares (in shares)	5,364	5,344		5,298	5,324
Basic earnings (loss) per share (in dollars per share)	$ 0.25	$ 0.71		$ (0.02)	$ 1.10
Diluted earnings (loss) per share (in dollars per share)	$ 0.24	$ 0.70		$ (0.02)	$ 1.07
Share-Based Payment Arrangement, Option [Member]
Dilutive effect of shares (in shares)	27	109		0	109
Restricted Stock Units (RSUs) [Member]
Dilutive effect of shares (in shares)	14	24		0	33

XML

Note 9 - Earnings Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total stock awards excluded from diluted EPS (in shares)	822	659	988	656
Assumed Conversion of Convertible Debt [Member]
Total stock awards excluded from diluted EPS (in shares)	608	608	608	608
Stock Awards that were Antidilutive [Member]
Total stock awards excluded from diluted EPS (in shares)	154	43	328	40
Stock Awards Subject to Performance Conditions [Member]
Total stock awards excluded from diluted EPS (in shares)	60	8	52	8

XML

Note 10 - Income Taxes (Details Textual)	6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Effective Income Tax Rate Reconciliation, Percent, Total	(93.50%)	4.10%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%

XML

Note 12 - Segment Data - Operating Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2022
Revenues		$ 58,749	$ 35,840	$ 109,202	$ 70,760
Total revenues		58,749	35,840	109,202	70,760
Gross profit (loss)		36,386	23,140	67,727	45,351
Gross profit (loss)		36,386	23,140	67,727	45,351
Operating expenses		32,391	18,939	68,326	38,027
Operating income (loss)		3,995	4,201	(599)	7,324
Nonoperating expense (income), net		611	(342)	1,429	1,363
Earnings (loss) before income taxes		3,384	4,543	(2,028)	5,961
Total inventories		28,039		28,039		$ 24,606
Operating Segments [Member]
Revenues	[1]	58,749	35,840	109,202	70,760
Total revenues	[1]	58,749	35,840	109,202	70,760
Gross profit (loss)		36,404	23,215	67,762	45,447
Gross profit (loss)		36,404	23,215	67,762	45,447
Operating expenses		32,391	18,939	68,326	38,027
Operating income (loss)		3,995	4,201	(599)	7,324
Nonoperating expense (income), net		611	(342)	1,429	1,363
Operating Segments [Member] | Clinical Genomics [Member]
Revenues		18,435	0	32,940	0
Total revenues		18,435	0	32,940	0
Gross profit (loss)		10,641	0	18,490	0
Gross profit (loss)		10,641	0	18,490	0
Total inventories		12,600		12,600		11,802
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Revenues		16,964	14,033	31,738	29,183
Total revenues		16,964	14,033	31,738	29,183
Gross profit (loss)		12,199	10,486	22,967	21,914
Gross profit (loss)		12,199	10,486	22,967	21,914
Total inventories		2,864		2,864		2,176
Operating Segments [Member] | Biopharmaceutical Development [Member]
Revenues		12,144	10,555	23,111	19,432
Total revenues		12,144	10,555	23,111	19,432
Gross profit (loss)		7,557	6,601	14,634	11,293
Gross profit (loss)		7,557	6,601	14,634	11,293
Total inventories		5,214		5,214		4,495
Operating Segments [Member] | Calibration Solutions [Member]
Revenues	[2]	11,206	11,252	21,413	22,145
Total revenues	[2]	11,206	11,252	21,413	22,145
Gross profit (loss)		6,007	6,128	11,671	12,240
Gross profit (loss)		6,007	6,128	11,671	12,240
Total inventories		7,361		7,361		$ 6,133
Corporate, Non-Segment [Member]
Gross profit (loss)	[3]	(18)	(75)	(35)	(96)
Gross profit (loss)	[3]	$ (18)	$ (75)	$ (35)	$ (96)

[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals

[2] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.

[3] Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.